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ABSTRACT 
 
Bilirubin (BR), a toxic waste product of degraded haem, is a potent antioxidant at 
physiological concentrations. To achieve the maximum benefit of BR, its intracellular 
level needs to be carefully regulated. A system comprising of two enzymes, haem 
oxygenase-1 (HMOX1) and cytochrome P450 2A5 (CYP2A5) exists in the endoplasmic 
reticulum (ER), responsible for regulating BR homeostasis.  This system is induced in 
response to oxidative stress. In this thesis, oxidative stress caused accumulation of these 
enzymes in mitochondria — major producers and targets of reactive oxygen species 
(ROS) — is demonstrated. To understand the significance of this intracellular targeting, 
properties of microsomal and mitochondrial BR metabolising enzymes were compared 
and the capacity of mitochondrial CYP2A5 to oxidise BR in response to oxidative stress 
is reported.  
 
Microsomes and mitochondrial fractions were isolated from liver homogenates of 
DBA/2J mice, administered with sub-toxic dose of pyrazole, an oxidant stressor. The 
purity of extracted organelles was determined by analysing the expressions and activities 
of their respective marker enzymes. HMOX1 and CYP2A5 were significantly increased 
in microsomes and even more so in mitochondria in response to pyrazole-induced 
oxidative stress. By contrast, the treatment did not increase either microsomes or 
mitochondrial Uridine-diphosphate-glucuronosyltransferase 1A1 (UGT1A1), the sole 
enzyme that catalyses BR elimination through glucuronidation. 
  
In response to pyrazole-induced oxidative stress, BR oxidation was enhanced not only in 
microsomes but also in mitochondria. The reaction in both control and pyrazole treated 
microsomes were blocked by up to 70% with anti-CYP2A5 antibody. By contrast, no 
CYP2A5 antibody inhibition on BR oxidation was observed in control mitochondria but 
was 55% inhibited in treated mitochondria. Antibody against adrenodoxin reductase 
(AdxR) (a component of mitochondrial monooxygenase system) had no effect on the 
microsomal BR oxidation, but the reaction was inhibited by up to 50% in mitochondria 
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after pyrazole treatment. As in microsomes, the antibody had no effect in control 
mitochondria.  
 
Inhibition study with ascorbic acid — a scavenger of ROS — was undertaken to 
determine the contribution of ROS to BR oxidation. In control microsomes, a slight 
inhibition of 5% in BR degradation was noted which was augmented to 22% after 
pyrazole treatment. The inhibition was 100% in control mitochondria but limited to 50% 
after pyrazole treatment.  
 
Mass spectrometry analysis reveals that in microsomes, biliverdin (BV), the main 
metabolite of CYP2A5-dependant BR oxidation was formed. Meanwhile, mitochondria 
produced predominantly dipyrroles, the products of BR scavenging ROS. Pyrazole 
treatment caused mitochondria to yield relatively similar amount of BV and dipyrroles. 
Enzyme kinetic analysis showed that mitochondrial and microsomal CYP2A5 have an 
equally strong affinity towards BR. Additionally, no initiation of apoptosis, as indicated 
by the absence of cytosolic cytochrome C was observed in treated liver.   
 
Collectively, these observations suggest that: i) both HMOX1 and CYP2A5 are recruited 
into mitochondria to regulate BR metabolism during oxidative stress; (ii) CYP2A5-
dependent BR oxidation in mitochondria is driven by the mitochondria-specific electron 
transfer chain; (iii) constitutive mitochondrial BR oxidation is driven un-enzymatically 
yet equally driven by ROS and CYP2A5 in response to oxidative stress; (iv) BR affinity 
to mitochondrial CYP2A5 is in the same range to that of microsomal CYP2A5; (v) 
mitochondrial BR is not eliminated by glucuronidation but recycled by CYP2A5 
oxidation to BV; and (vi) mitochondrial targeting of enzymes crucial for BR homeostasis 
is not associated with initiation of mitochondria specific apoptosis. It is thus submitted 
that targeting of key BR regulatory enzymes to mitochondria is an adaptive response to 
oxidative stress, aimed at mitochondrial protection against oxidative damage.  
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1. INTRODUCTION 
 
Mitochondria are essential organelles in regulating the life and death of cells. 
They produce energy through oxidative phosphorylation of the electron transfer chain 
(ETC), as well as regulate apoptotic proteins, which are essential for cells survival in 
critical conditions. In producing energy, mitochondria release reactive oxygen species 
(ROS), which if not controlled can lead to oxidative damage of the ETC and 
mitochondrial DNA (mtDNA). This can promote a vicious loop, where inefficient ETC 
will generate more ROS. Some of these ROS may permeate out of mitochondria and 
spread to the whole cell (Zorov et al., 2000; Zorov et al., 2006). As such, mitochondrial 
oxidative stress has been implicated in the progression of chronic diseases, such as 
cancers, neurodegenerative diseases, atherosclerotic diseases, and cardiovascular  
diseases, as well as in aging processes (Kidd, 2005; Sullivan and Brown, 2005; Fukui 
and Moraes, 2008; Seo et al., 2010). Thus, to counteract the deleterious effects of ROS 
and to maintain cellular homeostasis, mitochondria contain a number of antioxidant 
systems, such as glutathione, superoxide dismutase (SOD), glutathione peroxidase (GPx) 
(Tilak and Devasagayam, 2006; Mari et al., 2009) and potentially the bile pigment, 
bilirubin (BR), which is the focus of this thesis. 
 
BR is a product of haem degradation, catalysed initially by haem oxygenase 
(HMOX) and subsequently by biliverdin reductase (BVR). Though toxic at high 
concentrations, BR has been regarded as a potent cellular antioxidant at physiological 
concentrations, (Stocker et al., 1987a; Stocker et al., 1987b; Tomaro and Battle, 2002) 
and therefore, its levels require careful maintenance. In scavenging ROS, BR is broken 
down to more polar metabolites ranging from tripyrroles to dipyrroles that are readily 
excreted (Yamaguchi et al., 1995; Kunikata et al., 2000; Yamaguchi et al., 2002; Arthur 
et al., 2012; Abu-Bakar et al., 2013).   Recently, Abu-Bakar et al. (2011) has 
demonstrated a major role for microsomal CYP2A5 as BR oxidase, metabolising BR to 
predominantly biliverdin (BV).  During oxidative stress, microsomal BR oxidation can 
be induced following increased hepatic BR levels due to HMOX1 accumulation (Abu-
Bakar et al., 2005; Abu-Bakar et al., 2011). This induction is achieved as BR can 
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upregulate its own oxidation at sub-toxic concentrations   by delaying  the degradation of 
labile CYP2A5 enzyme that would stabilise the protein (Abu-Bakar et al., 2005; Abu-
Bakar et al., 2011; Abu-Bakar et al., 2012; Abu-Bakar et al., 2013).  
 
Accordingly, these findings are consistent with a proposition that HMOX1 and 
CYP2A5 work together for a rapid increase of BR to scavenge ROS and for a rapid 
removal of any excess BR amount by   oxidising it to nontoxic BV, once the stress has 
subsided. The high affinity of BR to CYP2A5 with Km of 1-2 μM (Abu-Bakar et al., 
2005; Abu-Bakar et al., 2012) seems to be ideal for this purpose. Consequently, these 
adaptive responses aim at maintaining intracellular BR homeostasis, keeping BR at 
sufficient cytoprotective concentrations as well as at safe tissue levels (Abu-Bakar et al., 
2005; Abu-Bakar et al., 2012; Abu-Bakar et al., 2013).                                                                                                                                                                                                                                                                                                                                       
 
Interestingly, CYP2A5 enzyme is also found in mitochondria, and can be 
upregulated in response to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) and pyrazole-
induced stress (Honkakoski et al., 1988; Genter et al., 2006). However, the function of 
mitochondrial CYP2A5 under oxidative stress needs to be clarified. It is possible that 
mitochondrial CYP2A5 can function as BR oxidase to circumvent its toxicity in this 
organelle. In this thesis, key enzymes that involved in mitochondrial BR metabolism 
were identified and compared to those in microsomes. Furthermore, the importance of 
CYP2A5-BR oxidation, plausibly for mitochondrial protection under oxidative stress 
condition, was also investigated. Pyrazole, a strong oxidant in endoplasmic reticulum 
(ER), as well as in mitochondria, was used in the study to induce the oxidative stress in 
both organelles (Lämsä et al., 2010; Bae et al., 2012).  
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2. LITERATURE REVIEW 
 
 
2.1 REACTIVE OXYGEN SPECIES (ROS)  AND OXIDATIVE STRESS 
 
 
Radical oxygen species (ROS) are small, highly reactive molecules, with one or 
more unpaired electrons, derived from molecular oxygen (O2). They include superoxide 
anion (O2
.-
), hydroxyl radical (OH
.-
) and hydrogen peroxide (H2O2). They are by-products 
of normal cellular functions of various organelles, such as mitochondria, peroxisomes 
and ER (microsomes) (Jezek and Hlavata, 2005). Although they are essential for  some 
physiological functions, excessive amounts can cause cellular damage as they readily 
attack macromolecules, such as  lipids, proteins, carbohydrates, and DNA. Therefore, 
cellular integrity is achieved through normal “ROS homeostasis” that is essentially 
maintained by a battery of cellular antioxidant systems (Jezek and Hlavata, 2005; 
Alfadda and Sallam, 2012).  
 
Exposure to toxic chemicals, radiation and pathogenic microorganisms often 
lead to formation of ROS which can react with proteins, lipids and nucleic acids leading 
to toxic / mutagenic effects (Nebert and Russell, 2002). Sustained detoxification of the 
increased ROS by systems that maintain ROS homeostasis may lead to insufficient 
antioxidant capacity to protect cells against ROS generated by normal physiological or 
pathological processes. Thus, cells enter a state of oxidative stress. If ROS homeostasis 
and cellular antioxidant capacity are not restored, cells will eventually undergo necrotic 
cell death, which in turn propagates the pathogenesis of chronic diseases, such as cancers, 
artherosclerotic diseases and cardiovascular diseases (Diplock, 1994; Willcox et al., 
2004). 
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2.1.1  SOURCES OF CELLULAR ROS 
 
 
There are various sources of ROS in mammalian cells. One of the many sources 
of O2
.- — the primary ROS molecule — is the catalytic activity of oxidoreductases, a 
group of enzymes that catalyse transfer of electrons from the donor (reductant) to the 
acceptor (oxidant).       
 
Generally, superoxide is a by-product of a specific oxidoreductase catalytic 
activity, except for reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase whose primary function is to catalyse the transfer of electrons from NADPH to 
molecular oxygen resulting in the generation of superoxide (Griendling et al., 2000). 
Other oxidoreductases that are potential sources of superoxide in mammalian cells 
include: 
 
 cyclooxygenase (Kukreja et al., 1986), an enzyme involved in biosynthesis of 
prostaglandins (Ricciotti and FitzGerald, 2011);   
 
 nitric-oxide synthase (Pou et al., 1992), the catalyst for production of nitric 
oxide, an important cellular signalling molecule vital for many biological 
processes, such as vasodilation and immune response (Gkaliagkousi and 
Ferro, 2011); 
 
 cytochrome P450 (CYP) enzymes (Zangar et al., 2004), catalysts for phase I 
metabolism of xenobiotics / endobiotics; and  
 
 mitochondrial reduced nicotinamide adenine dinucleotide 
(NADH):ubiquinone oxidoreductase, a component of ETC (Lambert and 
Brand, 2004).  
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Invariably, clearance of O2
.-
 leads to formation of other ROS. For example, 
conversion of O2
.-
 to water involves a two-step reaction where O2
.-
 is first converted to  
H2O2  by SOD. In turn, H2O2 is metabolised by catalase and GPx to water (Figure 2.1) 
(Dawes, 2006). Alternatively, in the presence of reduced transition metals, such as 
ferrous ion (Fe
2+
), H2O2 can give rise to a highly reactive OH
.- 
through catalytic  ion 
oxidation in Fenton reaction. This reaction is aggravated by O2
.-
 in  Haber-Weiss reaction 
by reducing ferric (Fe
3+
) to Fe
2+
 (Droge, 2002; Valko et al., 2007). 
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Figure 2.1 Reactive oxygen species (ROS) homeostasis in cell. During mitochondrial and endoplasmic 
reticulum (ER) metabolisms, leakages of electrons generate superoxide (O2
.-). O2
.- can be dismutated to 
H2O2 by superoxide dismutase (SOD). H2O2 can be detoxified by catalase and glutathione peroxidase 
(GPx). Oxidative perturbation of glutathione (GSH): glutathione disulphide (GSSG) ratio indicates 
oxidative stress in cell. Other critical ROS scavengers include peroxiredoxin (PRx) and thioredoxin (Trx2). 
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i. Mitochondrial sources of ROS 
 
Mitochondria can generate ROS during oxidative phosphorylation that involves 
a series of protein complexes in the inner mitochondrial membrane (IMM), called 
electron transport chain (ETC) (Figure 2.2). These processes are essential to generate 
metabolic energy from the breakdown of carbohydrates and fatty acids (Cooper and 
Hausman, 2009). 
 
The continuous reduction of molecular oxygen (O2) to water (H2O) by ETC 
generates O2
.- 
as an inevitable by-product and primary ROS (Fridovich, 1995; Droge, 
2002). The O2
.-  
accumulates  when electron flow slows down and when concentration of 
O2 increases (Turrens, 2003). About 1 to 4% of O2 in ETC is reduced to ROS (Chance et 
al., 1979; Nohl et al., 2005; Tilak and Devasagayam, 2006). They are mostly formed at 
Complexes I and III (Turrens et al., 1985; Turrens and Boveris, 1980;  Sugioka et al., 
1988; Chen et al., 2003) (Figure 2.2). In Complex I, O2
.-
 radicals are formed in the matrix 
side of the IMM (Figure 2.2). Succinate, the substrate of complex II, can also increase the 
production of radicals by complex I (de Vries, 1986; Liu, et al., 2002).  In complex III, 
O
.
2
-
 are produced on both side of IMM (matrix and intermembrane space) (Muller et al., 
2004). Oxidation of reduced ubiquinones (UQ), (UQH2) in Q cycle
1
 is regarded as an 
important process in formation of radicals at this site (Turrens et al., 1985; Kowaltowski 
et al., 2009). Presumably the intermembrane space ROS have easier access to cytosol 
through voltage dependent anion-selective channel (VDAC), as compared to matrix 
ROS, in which they have to cross the outer membrane and IMM (Sena and Chandel, 
2012).  
 
 
 
                                               
1
 Q cycle: This reaction creates semiquinone radical (UQ.-) at the Qp site of complex III, that faces intermembrane 
space. An electron of UQ.- at Qp is then transferred to Qn site (faces the mitochondrial matrix), to produce Qn UQ .-. 
The UQ.-  is changed to a reduced form (UQH2) by a second UQ
.-  that formed at Qp site (faces intermembrane space). 
O.2
- radicals may be formed from unstable UQ.-/UQ pair (Kowaltowski et al., 2009). 
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Production of mitochondrial superoxide is estimated to be 5 to 10-fold higher 
than that of cytosol and nucleus (Cadenas and Davies, 2000). In the mitochondria matrix, 
superoxide is further transformed into a relatively stable H2O2 by manganese (Mn)-SOD 
(Starkov and Wallace, 2006). In the intermembrane space, the conversion of O
.
2
-
 to H2O2 
is catalysed by copper (Cu) and zinc (Zn)-SOD (Weisiger and Fridovich, 1973; Okado-
Matsumoto and Fridovich, 2001). Production of mitochondrial ROS can initiate 
damaging reactions to mitochondrial macromolecules, as well as, to macromolecules 
outside of mitochondria as ROS can diffuse through mitochondrial membrane (Tilak and 
Devasagayam, 2006). It is noted that mitochondrial DNA (mtDNA) is especially 
susceptible to oxidative damage due to close proximity to ETC in the matrix, as well as 
lacking the protective DNA-associated proteins such as histones. Additionally, 
mitochondria need a sufficient supply of iron to maintain ETC complexes. Ineffectively 
metabolised iron overload by Mn-SOD can produce highly reactive OH
.-
 radical through 
Fenton reaction that can damage biological systems (Toyokuni, 1996; Atamna, 2004; 
Levi and Rovida, 2009). 
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 Figure 2.2 Generation of ATP and ROS by electron transport chain (ETC) in mitochondria. Electrons (e
-
), donated by NADH and 
FADH2, are passed through a series of protein complexes embedded in the inner membrane, via redox reactions to molecular oxygen. In the 
process, protons are pumped from the mitochondrial matrix to the intermembrane space, generating a proton gradient, and oxygen is reduced 
to form water. The gradient is used by ATP synthase to synthesize ATP. ROS are produced as a result of e
-
 escaping mostly from complex I 
and III, forming superoxide radicals in the matrix and intermembrane space. 
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  Mitochondria are also the site for haem biosynthesis, during which, free radicals 
may also be generated by oxidation and photochemical reactions of haem precursors — 
aminolevulinic acid (ALA) and protoporphyrin-IX (PP-IX) — which are both 
synthesised in the mitochondria (Ryter and Tyrrell, 2000). Under physiological 
condition, the breakdown of free haem catalysed by haem oxygenase-2 (HMOX2) 
releases Fe
2+
, which amplifies  Fenton reaction to convert peroxide to hydroxyl radical 
(Gozzelino et al., 2010) (Figure 2.1). 
 
In addition, mitochondria are critical regulators of intracellular calcium (Ca
2+
) 
levels to stimulate and control oxidative phosphorylation and induce permeability of 
mitochondrial inner membrane (Gunter et al., 2004). The accumulation of Ca
2+
 has been 
shown to increase production of mitochondrial ROS. The mechanism underlying this is 
uncertain but has been linked to mitochondrial permeability transition (MPT)
2
. For 
example, Hansson et al (2008) showed that brain-derived mitochondria and human liver 
mitochondria have a sustained increment of ROS production following calcium-induced 
MPT. It was thought that the bioenergetic consequences of MPT leading to loss of 
detoxification function mainly caused the increased ROS. 
 
 
ii. Endoplasmic Reticulum Sources of ROS  
 
Endoplasmic reticulum (ER) can generate ROS during metabolism of exogenous 
and endogenous compounds, as well as, in cellular protein synthesis. The metabolism of 
xenobiotic is performed by cytochrome P450 (CYP) enzymes, a family of haemoproteins 
localised in the ER, predominantly in the liver (Josephy, 1997; Parkinson, 2001). 
 
                                               
2  MPT: increase permeability of mitochondrial membrane caused by opening of a large pore in the inner membrane. 
The membrane is normally closed and can be opened by Ca2+ overloading, oxidative stress and other factors. This 
result in degeneration of mitochondrial outer membrane and released of cytochrome C into cytosol (Tilak and 
Devasagayam, 2006). 
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In humans and other mammals, CYP families 1-4 are generally regarded as 
xenobiotic-metabolising enzymes (XMEs), responsible for the oxidative clearance of 
drugs and environmental chemicals. They exhibit a broad substrate selectivity that is 
important in protection against damages by these chemicals. Accordingly, these XMEs 
form part of a coordinated system for xenobiotic clearance, which also includes other 
enzymes such as glucuronosyltransferases and a series of nuclear receptors/transcription 
factors that regulate the response to chemical challenge (Josephy, 1997). 
 
CYP enzymes commonly catalyse the oxidation of carbon and heteroatom centres 
on lipophilic chemicals to make them more hydrophilic by using molecular oxygen and 
NADPH as a reducing cofactor. However, catalytic cycle of CYP enzymes can generate 
O2
.-
 and H2O2 through a process called uncoupling  (Josephy, 1997; Schlezinger et al., 
1999; Parkinson, 2001) . When substrate and CYP enzymes are poorly coupled, these 
ROS can be produced in excess and leak subcellularly, hence rendering the cycle futile 
(Bondy and Naderi, 1994). According to Shertzer et al (2004), certain known CYP 
enzymes that are affected by this process include CYP1A, CYP2E1, CYP2B4 and 
CYP3A. Uncoupling is aggravated when CYP enzymes-substrate specificity is 
promiscuous.  For example, much of the toxicities of environmental pollutants such as 
TCDD and polychlorinated biphenyls (PCBs) depend on ROS generated when CYP1A 
cycle is uncoupled (Schlezinger et al., 1999; Schlezinger and Stegeman, 2001; 
Schlezinger et al., 2006; Lu et al., 2009). Interestingly, subsequent altered redox status 
caused by these ROS can lead to oxidation of certain target molecules, particularly BR 
(De Matteis et al., 1991; Zaccaro et al., 2001; Pons et al., 2003; De Matteis et al., 2006). 
Finally, even in the absence of substrates, CYP can oxidise NADPH and subsequent 
uncoupling can persist, thus significantly promoting the overall formation of cellular 
ROS. 
 
ER is also the major site for cellular protein synthesis (Chakravarthi et al., 2006). 
To accommodate protein folding, ER lumen possesses oxidising condition for disulphide 
bond formation which may also contribute to the formation of ROS that leads to ER 
stress, a condition where ER loses its protein folding capacity (Bhandary et al., 2012). 
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Unfolded proteins can accumulate as a result of the oxidising condition, leaking Ca
2+
 
from lumen into cytosol, and increase ROS production in mitochondria (Leem and Koh, 
2012; Bravo-Sagua et al., 2013). This in turn activates adaptive unfolded protein 
response (UPR) to restore protein folding and ER homeostasis. However, unresolved 
persistent stress and ER homeostasis will shift UPR towards apoptosis to protect the 
organism (Chakravarthi et al., 2006). 
 
 
2.2 ADAPTIVE RESPONSE TO OXIDATIVE STRESS 
 
 
In normal cells, ROS homeostasis is maintained by antioxidant enzymes as 
depicted in Figure 2.1, and non-enzymatic, low molecular mass ROS scavengers, such as 
ascorbic acid, α-tocopherol, and most importantly glutathione (Leibovitz et al., 1980; 
Valko et al., 2007). 
 
Glutathione is a primary low-molecular weight thiol in all aerobic cells (Jezek 
and Hlavata, 2005).   In normal cells, more than 90% of glutathione exist in the reduced 
form (GSH) and less than 10% as glutathione disulfide (GSSG), the oxidised state. The 
GSH: GSSG ratio is critical to ensure cell’s capability of immediately neutralising any 
damaging ROS.  Upon oxidative stress, GSH is readily reactive and capable of reducing 
ROS with the help of glutathione peroxidase (GPx) and in turn produce GSSG. 
Glutathione reductase (GRx) can regenerate GSH from GSSG. These enzymes as well as 
SOD represent the main mitochondrial defence system in maintaining ROS homeostasis 
(Baranano et al., 2002; Mari et al., 2009). 
 
Alteration of the GSH:GSSG ratio through exposure to toxic chemicals, 
pathogenic microorganisms and radiation, amongst others, is indicative of oxidative 
stress, which in turn invokes activation of cytoprotective genes to counteract oxidative 
damage. For example, ROS generated by xenobiotics can be detoxified through the 
reaction of GSH. ROS may also be formed through the catalytic activity of CYPs, further 
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increasing the consumption of GSH. This may lead to alterations in the ratio of GSH to 
GSSG, leaving insufficient GSH to protect the cell against ROS generated by normal 
physiological processes (Dalton et al., 1999; Valko et al., 2007). 
  
At this point, the cells invoke a second tier of damage control, where the stress-
responsive transcription factor NF-E2 related factor-2 (Nrf2) is activated via a redox 
sensitive signalling cascade (Kang et al., 2005).  In turn, Nrf2 regulates the coordinated 
activation of a battery of genes that encode certain phase II drug-metabolising enzymes 
that include NAD(P)H quinone oxidoreductase (NQO1) and glutathione S-transferase A2 
(GST2A) (Kang et al., 2005), HMOX1 (Alam et al., 1999), and CYP2A5 (Abu-Bakar et 
al., 2007). These enzymes serve to neutralise ROS and electrophiles, biosynthesise 
glutathione, direct xenobiotic efflux and remove oxidised proteins. The net result is to 
scavenge ROS and conjugate electrophiles, which serve to limit oxidative damage and to 
detoxify cells. 
 
 
2.2.1 CYTOPROTECTION OF HAEM OXYGENASE AGAINST 
OXIDATIVE DAMAGE 
 
 
The microsomal haem oxygenase (HMOX), also known as heat shock protein 
32, catalyses the initial and rate-limiting step in haem degradation. It exists in two forms: 
an inducible enzyme, HMOX1, and a constitutive form, HMOX2 (Ryter and Tyrrell, 
2000; Maines, 2005). HMOX1, a 32kDa protein, is conventionally localised in ER of 
many tissues and cell types. It can be induced in wide variety of tissues, particularly the 
liver by a variety of physiological stimuli, such as hyperoxia, shear stress, and non-
physiological stimuli, such as heavy metals, ultraviolet light, and H2O2 (Maines, 1997; 
Agarwal and Nick, 2000).  By contrast, HMOX2, a 36 kDa protein, is constitutively 
expressed in mitochondria of brain, testes, nephron, endothelium and liver (Agarwal and 
Nick, 2000). Because its expression is not inducible, it is assumed to regulate haem 
degradation during normal physiologic conditions.  
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HMOX catalyses the first step in haem degradation, where it is converted to BV. 
In this reaction, free Fe
2+
 is liberated from haem and carbon monoxide (CO) is released 
as by-product (Figure 2.3) (Gozzelino et al., 2010). BV is then reduced to lipophilic BR 
by BVR. These catalytic products, if present at above physiological concentrations, are 
cytotoxic. For instance, free Fe
2+
 can potentiate oxidative stress through ROS generation 
via the Fenton reaction (Gozzelino et al., 2010). CO can bind to haemoglobin and 
cytochrome C oxidase (COX), thus decreasing O2 in arterial blood and inhibiting 
mitochondrial energy metabolism, respectively (Piantadosi, 2008). BR may physically 
interact with cell membranes which in turn, disturbs lipid polarity, redox states and 
causes neonatal jaundice as well as brain damage (Tomaro and Batlle, 2002; Tell and 
Gustincich, 2009).  
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Figure 2.3 Bilirubin metabolism pathways in the liver. The major pathway of BR degradation is 
via UGT1A1 enzyme glucuronidation. This diagram also shows that BR can be oxidised to BV by the 
enzyme CYP2A5. The non-enzymatic pathway involves BR oxidation by ROS to produce oxidative 
metabolites.  
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However, at physiological concentrations, these compounds have important 
biological functions. For instance, the iron may be utilised in haemoglobin synthesis as 
evident in HMOX1 deficient mice that developed iron deficiency anaemia as a result of 
low serum iron levels (Poss and Tonegawa 1997; Yachie et al. 1999). On the other hand, 
CO has recently been acknowledged as a second messenger of the anti-inflammation 
signalling transduction pathways in various tissues that can consequently promote overall 
anti-apoptotic effect (Maines 1997; Brouard et al., 2002;  Micheau and Tschopp, 2003; 
Arruda et al., 2004; Wegiel et al., 2008; De Backer et al., 2009; Gozzelino et al., 2010). 
Additionally, physiological concentrations of CO are important in maintaining 
vasodilation (Ndisang et al., 2004). 
 
BR, the final product of haem degradation is known for its anti-mutagenic and 
anti-oxidative properties (Stocker and Peterhans, 1989; Bulmer et al., 2008b).  Evidence 
for antioxidant effects of BR in vivo has been obtained from a HMOX1 deficient patient 
with low serum BR who is vulnerable to oxidative stress-mediated endothelial cell injury 
(Yachie et al., 1999). Additionally, epidemiology studies linking BR to low risk of 
oxidative stress-related chronic diseases have also been reported (discussed further in 
section 2.2.2) (Heyman et al., 1989; Schwertner et al., 1994; Djousse et al., 2001; 
Temme et al., 2001).  
 
Given their toxicity at high concentrations, it is evident that the products of 
haem degradation need to be tightly regulated to maintain homeostasis, which is crucial 
for cellular survival. This thesis will focus on the regulation of intracellular BR 
especially in cellular response to oxidative stress. 
 
 
2.2.2 REGULATION OF CELLULAR BILIRUBIN  
 
 
In the blood, the highly hydrophobic BR is bound to serum albumin to be 
delivered to the liver where it is conjugated with glucuronic acid to form soluble mono- 
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and di-glucuronides. This process is solely catalysed by the microsomal Uridine 
diphosphate glucuronyltransferase 1A1 (UGT1A1) enzyme (Tukey and Strassburg, 2000; 
Vitek and Ostrow, 2009) (Figure 2.3). BR glucuronides are then excreted into the bile by 
a multidrug resistance-associated protein 2 (MRP2) (Kamisako et al., 2000). In the 
gastrointestinal tract, the glucuronides can be metabolised by colonic bacteria to 
urobilinogen, stercobilinogen and stercobilin (Kamisako et al., 2000; McDonagh, 2010). 
 
Serum concentrations of BR exceeding the binding capacity of albumin are 
associated with brain damage in neonatal jaundice and in individuals with the rare 
congenital condition of Crigler–Najjar syndrome (deletion of UGT1A1 activity) (Ihara et 
al., 1999; Kaplan and Hammerman, 2011). However, serum BR concentrations rarely 
approach these toxic levels and approximate 10 µM in the general population, which is 
30-60 times below the reported toxic concentration of BR (Bulmer  et al., 2008a). 
 
Interestingly, mildly elevated serum BR (2-9 times above the concentrations of 
the general population) has been shown to be associated with reduction in the prevalence 
and incidence of cancers and cardiovascular disease (Rigato et al., 2005; Vitek and 
Schwertner, 2008; Horsfall et al., 2011). These protective effects are also reported in 
individuals with Gilbert's Syndrome (GS), a congenital condition characterised by mild 
and chronic hyperbilirubinemia unconnected with either haemolysis or liver disease 
(Vitek et al., 2002; Jiraskova et al., 2012).  
 
GS patients carry the genotype UGT1A1*28/*28, a homozygous insertion of one 
base pair that resulted in a decrease in BR glucuronidation activity, which leads to an 
increase in the level of serum BR, ranging from 20 - 90 µM (Gil and Sasiadek, 2012). 
The UGT1A1*28 allele has been associated with a reduction of the prevalence of chronic 
diseases. For example, a Czech Republic exploratory case-control study on 777 
colorectal cancer (CRC) patients and 986 controls indicated that UGT1A1*28 allele is 
associated with a 20% decrease in risk of CRC and each 1 µM  decrease in serum BR is 
associated with a 7% increase of CRC risk (Jiraskova et al., 2012). Similarly, in a three-
year follow-up of healthy GS subjects, none of them developed new-onset symptomatic 
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ischemic heart disease, whilst 4.3% of control subjects with normal serum BR levels 
developed the disease (Vitek et al., 2002). In a Framingham Heart Study population, 
UGT1A1 mutation with increased serum BR concentration showed a strong correlation 
to lower risk of cardiovascular diseases (Lin et al., 2006). These studies indicate 
preventive effects of BR on cancer and cardiovascular disease development. 
Additionally, BR protective role has also been found in end stage kidney disease, 
diabetes mellitus and diabetic nephropathy (Chin et al., 2009; Han et al., 2010). 
However, the mechanism by which BR confers such protection is still obscure. 
 
It has been established that BR can act as an efficient antioxidant. One 
hypothesis for this efficiency is that BR can be recycled through a cyclic redox cycle in 
which BR is oxidised to BV when it scavenges ROS, a mechanism that is similar to the 
GSH/GSSG regeneration.  BV, in turn, is reduced to BR by BVR, an abundant and 
ubiquitous enzyme with high turnover rate. In this way, BR could be recycled as 
antioxidant many times over and capable of protecting against greater concentrations of 
ROS, even though its cellular concentrations is approximately 10,000 times lower than 
that of GSH, the principal cellular antioxidant (Baranano et al., 2002;  Sedlak and Snyder 
2004; Sedlak et al., 2009). 
 
However, in 2004, McDonagh argued against the concept of BV being the main 
product of ROS attack on BR. It has been demonstrated that once BR is oxidised by 
ROS, it is broken down to more polar di- and tripyrroles that are readily excreted in the 
urine (Kobayashi et al., 2003; Arthur et al., 2012; Abu-Bakar et al., 2013), unlike that of 
GSH system. It has been proposed that rather than being eliminated, any excess of BR is 
constantly monitored and oxidised to BV by CYP2A5 (further discussed in section 
2.2.3). Indeed, the significance of CYP2A5 in cytoprotection has been indicated in vitro, 
where overexpression of CYP2A5 in a human liver cell line reduced BR- induced 
apoptosis (Kim et al., 2013). As BV is a more hydrophilic compound as compared to BR, 
it is possible for it to be present at a higher concentration without causing cytotoxicity. In 
this regard, BV could be reduced back to BR by BVR, depending on the ROS levels. 
Additionally, BV has also been shown to possess reducing ability (Stocker, 2004; Jansen 
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et al., 2010) and thus could provide a surplus of antioxidant capacity. Finally, it is also 
possible that BV could act as a negative feedback regulator for CYP2A5 activity, once 
BV level reached saturation. Whatever the fate of BV is, the proposed adaptive response 
to cellular stress aims to provide a rapid availability of BR antioxidant capacity whilst 
curbing its toxicity.  
 
In this way, the proposed BR-BV model would parallel the recycling of GSH, 
another chain-breaking antioxidant. Both systems involve a single chemical that exists in 
two states: an oxidised form and a reduced form. In both cases, the BV and reduced GSH 
predominate under healthy conditions and are part of oxidative stress response which is 
induced when cells are challenged with a wide range of toxic insults (discussed in 2.2). 
When either system is disrupted, oxidative stress increases and cells die. 
 
Importantly, an in vitro study using human embryonic kidney cells (HEK293) 
and HMOX knock-out mice indicated that BR complements GSH cytoprotection: the 
water-soluble GSH primarily protects water soluble proteins and the lipophilic BR 
protects lipids (Sedlak et al., 2009) such as membrane structures from oxidation . The 
study also showed that mice with deletion of HMOX2, which generates BV, display 
greater lipid than protein oxidation, while the reverse holds for GSH depletion. 
Furthermore, RNA interference depletion of BVR increases oxidation of lipids more than 
protein and depletion of BVR or GSH augments oxidative-stress related cell death 
(Sedlak et al., 2009). 
 
 
2.2.3 CONCERTED INDUCTION OF BILIRUBIN PRODUCTION AND 
OXIDATION 
 
The concerted induction of microsomal HMOX1 and CYP2A5 in response to 
oxidative stress is thought to regulate BR homeostasis, in order to protect ER against 
oxidative damage (Abu-Bakar et al., 2005; Abu-Bakar et al., 2013). In response to 
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chemical-induced oxidative stress, Nrf2 is activated to induce the expression of HMOX1 
and CYP2A5 in the mouse liver (Alam et al., 1999; Abu-Bakar et al., 2007; Lämsä et al., 
2012). In turn, HMOX1 increased BR production to scavenge elevated ROS. Upon 
oxidation by ROS, BR is broken down to polar BR oxidative metabolites (BOMs). These 
BOMs include dipyrroles, tripyrroles and propentdyopent (De Matteis et al., 2006; Abu-
Bakar et al., 2011; Arthur et al., 2012), and are excreted in the urine (Kobayashi et al., 
2003; Arthur et al., 2012).   
 
The excess of intracellular BR is predominantly oxidised by CYP2A5 to BV 
instead of by UGT1A1-catalysed glucuronidation (Arthur,  2010). The role of CYP2A5 
and its human orthologue CYP2A6 as BR oxidase was recently demonstrated in vitro 
using liver microsomes and the recombinant enzymes (Abu-Bakar et al., 2011; Abu-
Bakar et al., 2012). These studies indicated that coumarin (the diagnostic substrate of 
CYP2A5 and CYP2A6) and antibodies raised against these metabolising enzymes 
suppressed BR  by about 90% (Abu-Bakar et al., 2005; Abu-Bakar et al., 2012). BR also 
significantly inhibited 7-hydroxylation of coumarin by CYP2A5 and CYP2A6, with an 
IC50 almost equal to the substrate concentration (Abu-Bakar et al., 2005; Abu-Bakar et 
al., 2012). The affinity of BR for the CYP2A5 and CYP2A6 is in the same range of their 
diagnostic substrate coumarin (Ki(BR) = 0.7-2.2 µM; Km(coumarin) = 0.5-2.0  µM) (Abu-
Bakar et al., 2005; Abu-Bakar et al., 2012). Furthermore, in vitro incubation of 
recombinant CYP2A5 and CYP2A6 with BR produced predominantly BV and minor 
amounts of dipyrroles (Abu-Bakar et al., 2011; Abu-Bakar et al., 2012). In support of the 
experimental data, docking analysis using the crystal structure of CYP2A6 indicated that 
the enzymatic BR oxidation occurs at the CYP2A6 active site via a mechanism 
producing maximal amounts of BV (Abu-Bakar et al., 2012).  
 
Collectively, these observations presented BR as a high affinity endogenous 
substrate for microsomal CYP2A5 and CYP2A6 and that its oxidation by these enzymes 
generated primarily BV. This, in turn, lends support to the proposition that the CYP2A5 
is one of the enzymes driving the BR redox cycle, crucial for maintaining optimal BR 
antioxidant activity (discussed in section 2.2.2). 
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The role of CYP2A5 as a part of the HMOX1 antioxidant system is further 
reinforced by the observation that the Nrf2-dependent CYP2A5 induction paralleled but 
followed the induction of HMOX1 by 5-10 hours interval (Abu-Bakar et al., 2005). 
Under this condition, the CYP2A5-dependent BR oxidation was significantly increased 
(Abu-Bakar et al., 2005). At elevated concentrations, BR induced its own oxidation 
through stabilising the labile CYP2A5 protein. This is evidenced when the CYP2A5 
protein half-life was increased as a result of BR co-treatment with cycloheximide, a 
protein synthesis inhibitor (Abu-Bakar et al., 2011). In fact, Aida and Negishi (1991) 
demonstrated that CYP2A5 mRNA is also stabilised when mice were treated with 
pyrazole. Collectively, these observations would be consistent with CYP2A5 serving to 
clear the BR generated by HMOX1 to ensure that levels of this essential but toxic 
compound do not exceed a safe threshold. This system is highly efficient as BR, a high 
affinity substrate with an ideal Km of 1-2 µM, is able to regulate its own oxidation in 
order to maintain the optimal intracellular levels well below the toxic levels of >10 µM. 
 
Further evidence demonstrating CYP2A5 cytoprotective role include: (a) the 
mouse strain DBA/2 known to have high constitutive activity of CYP2A5 is resistant to 
metal-induced oxidative stress (Hata et al., 1980; Kershaw and Klaasen, 1991; Liu, et al., 
1992; Sendelbach et al., 1992); (b) the constitutive expression of CYP2A5 is maintained 
by the Nrf2 pathway (Lämsä et al., 2010), suggesting a major role in homeostatic 
function; and (c) the overexpression of CYP2A5 in mouse liver cell lines reduced BR-
mediated apoptosis (Kim et  al., 2013).  
 
An interesting preliminary observation that is crucial to this thesis is that 
HMOX1 and CYP2A5 can also be induced in the liver mitochondria in response to 
chemical-induced oxidative stress (Genter et al., 2006). Furthermore, mitochondrial 
CYP2A5 induction is associated with Nrf2 pathway (Lämsä et al., 2012).  The role of 
such induction is unknown. It is plausible that HMOX1 and CYP2A5 could potentially 
play a role in maintaining BR homeostasis in mitochondria, as observed in ER (Figure 
2.4). 
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Figure 2.4 Proposed regulations of key enzymes in bilirubin metabolism in mitochondria and endoplasmic reticulum (ER) during 
oxidative stress. During oxidative stress, induced microsomal (ER) HMOX1 and CYP2A5, and cytosolic BVR are targeted to mitochondria, 
presumably to induce antioxidant bilirubin regulation (red arrows). The microsomal UGT1A1, the sole enzyme that catalyses bilirubin 
glucuronidation for excretion is absent in mitochondria. The CYP2A5 induction paralleled but followed the HMOX1 induction by several hours 
(Abu-Bakar et al., 2005). 
88 followed the induction of microsomal HMOX1 by several hours 
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3. RESEARCH PROBLEMS 
 
 
Bilirubin production from haem in mitochondria is maintained by the resident 
non-inducible HMOX2 and the cytosolic BVR that is targeted to mitochondria (Agarwal 
and Nick, 2000; Converso et al., 2006). In response to oxidative stress, BR production in 
mitochondria is heightened by the reaction catalysed by the HMOX1 and BVR. Ten to 
20% of the inducible microsomal HMOX1 and cytosolic BVR are targeted to the inner 
mitochondrial membrane under oxidative stress conditions (Srivastava and Pandey, 1996 
; Converso et al., 2006; Bindu et al., 2011). On the other hand, high BR levels can inhibit 
COX and induce mitochondrial membrane permeability that eventually leads to 
mitochondrial apoptosis (Rodrigues et al., 2002; Malik et al., 2010). Therefore, why is 
there a need for HMOX1 and BVR to be targeted to mitochondria? Is it possible that BR 
is also an antioxidant in mitochondria, as observed in microsomes? Since UGT1A1, the 
main conjugation enzyme and detoxification pathway of BR is not present in 
mitochondria, how is BR maintained at a physiological concentration in this organelle? 
As it has been shown that BR oxidation can provide cytoprotection when its 
glucuronidation pathway is deficient (Cuperus et al., 2009; Tell and Gustincich, 2009), 
could the mitochondrial cytochrome P450 system play a role in BR oxidation, and in 
turn, maintain local BR homeostasis in protecting mitochondria against BR toxicity? 
 
The microsomal CYP enzymes can be imported into inner mitochondrial 
membrane by way of: (i) direct canonical mitochondrial-targeting signals after synthesis 
in cytosol; or (ii) localisation of microsomal CYPs in mitochondria after amine (NH2)-
terminus processing that cause diminished CYPs incorporation and retention in ER (Ahn 
and Yun, 2010). Consequently, these allow mitochondrial CYP enzymes to adopt the 
mitochondrial monooxygenase system, which include a protein adrenodoxin reductase 
(AdxR). Most mitochondrial CYPs are involved in the metabolism of steroids 
(Hanukoglu, 1996).  
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The existence of BR oxidase in mitochondrial membrane was first proposed by 
Brodersen and Bartels (1969). This was further supported by studies that showed that 
significant BR oxidation in extrahepatic tissues, such as the intestine (Yokosuka and 
Billing, 1987) and brain (Hansen et al., 1999), occurred in the inner mitochondrial 
membrane. Although its activity seemed dependent on cytochrome C and O2, the 
responsible enzyme could not be confirmed as a CYP oxidase. Subsequently, enzymatic 
oxidation of BR in hepatic mitochondria was also demonstrated by Cardenas-Vazquez et 
al (1986). 
 
Interestingly, CYP2A5 a known microsomal BR oxidase, is constitutively 
expressed in mitochondria (Genter et al., 2006) and the CYP2A5-dependent coumarin 7-
hydroxylation (COH activity) is almost as high as in microsomes (Honkakoski et al., 
1988). In response to chemically-induced ER stress, mitochondrial COH activity 
increased by 4-fold (Honkakoski et al., 1988). Furthermore, the expression of CYP2A5 in 
mitochondria is dependent on the Nrf2 pathway (Lämsä, 2012; Lämsä et al., 2012), 
suggesting protective role of CYP2A5 in mitochondria. These observations lend support 
to my hypothesis that mitochondrial CYP2A5 may be part of the machinery that protects 
mitochondria against oxidative stress. 
 
 
3.1    RESEARCH QUESTIONS 
 
 
It has been shown that the CYP2A5 enzyme can be targeted to mitochondria 
during oxidative stress. However, the exact role of CYP2A5 in mitochondria, particularly 
in relation to BR metabolism is currently unknown.  The question then arises as whether 
key enzymes regulating BR in microsomes, the HMOX1, CYP2A5, UGT1A1 and BVR 
are targeted to mitochondria when challenged with oxidative stress. Is BR a substrate for 
the CYP2A5 in mitochondria? Is BR oxidation increased in mitochondria during 
oxidative stress?  What are the products of mitochondrial CYP2A5-mediated BR 
oxidation? This thesis addresses the above questions and investigates the role of CYP2A5 
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in mitochondria pertaining to BR metabolism under the condition of pyrazole-induced 
oxidative stress. 
 
 
3.2 WORKING HYPOTHESES 
   
  
 Considering the absence of UGT1A1 in mitochondria and that the CYP2A5 
enzyme has been indicated in microsomal BR regulation, the CYP2A5 constitutive 
presence and intracellular targeting during oxidative stress to mitochondria might also be 
linked to BR regulation in this organelle. The capacity of mitochondrial CYP2A5 to 
oxidise BR has never been reported. Thus, this thesis will address the following working 
hypotheses: 
 
1) Enzymes regulating microsomal BR metabolism, HMOX1 and CYP2A5 are 
targeted to mitochondria during oxidative stress to regulate BR levels. 
2) Mitochondrial BR metabolism is comparable to that of microsomes during 
oxidative stress. 
3) Mitochondrial CYP2A5-mediated BR oxidation activity is driven by a different 
monooxygenase system than that of ER. 
4) Mitochondrial BR oxidation products are comparable to those of microsomes. 
5) Upregulation of mitochondrial BR oxidation can confer mitochondrial 
cytoprotection. 
 
Addressing these research questions will give insight to new therapeutic target 
given that mitochondrial oxidative damage is a crucial event in many pathologies. 
Expectantly, this mitochondria-targeted antioxidant therapy may offer a better clinical 
intervention and improved prognosis in these diseases. 
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3.3 RESEARCH STRATEGY 
 
To test the proposed working hypotheses the following strategy was adopted: 
 
A) Identification and characterisation of key BR regulation enzymes in 
mitochondria 
 
Aim: 
i) Establishment of isolation method for the preparation of highly enriched 
organelles; cytosol, microsomes and mitochondria.   
ii) To compare the effect of pyrazole on hepatic microsomal and mitochondrial 
expressions of HMOX1, CYP2A5, BVR and UGT1A1 proteins and enzyme 
activities. 
 
Experimental procedure: 
Subcellular fractionations by differential centrifugation methods were compared so 
as to come up with the best protocol. This is crucial so that presence of a given 
enzyme cannot be explained on the basis of cross organelle contamination. 
Microsomes and mitochondria were extracted from treated and non-treated mice 
livers using the pre-established protocols. Their purity was determined at protein 
and activity levels of respective marker enzymes. The identity of each protein of 
interest was confirmed by Western immunoblotting and their relative enzyme 
activities were measured spectrometrically (procedures are outlined in Chapter 4). 
Microsomal and mitochondrial protein expressions and enzyme activities were 
appropriately compared. 
 
B) Study on effects of pyrazole treatment on mitochondrial BR degrading activity 
 
Aim: 
i) To investigate the effect of pyrazole on BR degrading activity in both 
microsomes and mitochondria. 
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ii) To investigate the role of CYP2A5 in the regulation of mitochondrial BR 
metabolism, in comparison to microsomes. 
 
Experimental procedure:  
The BR degradation activities in isolated microsomal and mitochondrial were 
investigated and compared by determining the rate of substrates disappearance 
(spectrometrically) and metabolites production (HPLC-MS/MS). BR oxidation 
inhibition with anti-CYP2A5 antibody, anti-AdxR antibody and ascorbic acid were 
performed in order to determine the involvement of mitochondrial CYP2A5 and 
ROS in BR oxidation (procedure outlined in Chapter 4). The reactions were 
compared to its microsomal counterpart. Additionally, the extent of hepatic 
oxidative damage was assessed by mitochondrial cytochrome C release into 
cytosol, a key initiator event of apoptosis.  
 
 
C) Study on the catalytic properties of mitochondrial CYP2A5 in oxidising BR 
 
Aim: 
i) To determine whether BR can inhibit mitochondrial CYP2A5 activity. 
ii) To determine the affinity of BR to mitochondrial CYP2A5 enzyme. 
iii) To assess the metabolite profile of CYP2A5 catalysed BR metabolism. 
 
 Experimental procedure: 
In mitochondria, hydroxylation of different concentrations of coumarin (substrate 
specific for CYP2A5) was performed in the presence of increasing amounts of BR 
as inhibitor. Enzyme kinetic parameters was determined and evaluated against 
those in microsomes. Ascorbic acid was used to block the BR oxidation caused by 
ROS and to distinguish between the ROS and CYP2A5 dependant BR metabolite 
profile. 
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4.  METHODS AND MATERIALS 
 
 
4.1 CHEMICAL REAGENTS AND ANTIBODIES 
 
All chemicals and reagents are listed in Appendix 1. 
 
 
4.2 LABORATORY ANIMALS AND TREATMENT 
 
 
The DBA/2J inbred strain of mouse was chosen as the constitutive expression of 
CYP2A5 in this strain is the highest amongst common laboratory strains (Wood and 
Conney, 1974; Wood and Taylor, 1979; Juvonen et al., 1985; Lang et al., 1989). Earlier 
studies linking CYP2A5 induction with oxidative stress used this strain (Abu-Bakar et 
al., 2004; Abu-Bakar et al., 2005; Abu-Bakar et al., 2007; Abu-Bakar et al., 2011; Abu-
Bakar et al., 2012; Abu-Bakar et al., 2013). Additionally, this strain was known to be 
resistant to metal-induced oxidative stress (Hata et al., 1980; Kershaw and Klaasen, 
1991; Liu et al., 1992; Shaikh et al., 1993), an attribute that was thought to be partly 
related to the high constitutive expression of CYP2A5 (Abu-Bakar, 2006).  
 
In this study, twelve 7-9 weeks old DBA/2J male mice (Animal Resources 
Centre, Western Australia) were randomly divided into three groups of control animals 
and   three groups of treated animals (2 mice per group).  They were maintained at a 12 
hour light / dark cycle, and had access to standard rodent chow ad libitum.  
 
To invoke oxidative stress, these mice were given intra-peritoneal injection of 
200 mg pyrazole / kg body weight once daily, for 3 consecutive days (Honkakoski et al., 
1988; Gilmore and Kirby, 2004).  The animals in the control groups were given normal 
saline only. The mice were sacrificed 24 hours after the last injection by CO2 overdose 
and their livers were excised. All the experimental procedures were approved by and 
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conducted in accordance with, National Health and Medical Research Council (NHMRC) 
Code of Practice for care and use of experimental animals, and approved by the 
Queensland Forensic and Scientific Services Animal Ethics Committee (FSS-AEC 
Approval No. 10P01). 
 
The pyrazole doses used in this study were known to cause ER stress in the 
mouse liver, as evidenced by an increase in the amount of glucose-regulated protein 78 
(GRP78), a marker for adaptive ER stress responses (Gilmore and Kirby, 2004; Nichols 
and Kirby, 2008). Pyrazole is also known to induce mitochondrial Ca
2+
 accumulation and 
to increase ROS production in mitochondria of human
3
 and mouse
4
 cell lines (Bae et al., 
2012). These observations support the proposition that ER stress often results in the 
increased loading of Ca
2+
 in mitochondria (Gorlach et al., 2006; Deniaud et al., 2008) 
and sustained  accumulation of Ca
2+ 
in the matrix of mitochondria stimulates 
mitochondrial metabolism. This, in turn disrupts the ETC (Cederbaum and Rubin, 1974; 
Deniaud et al., 2008), which leads to the increased production of ROS in mitochondria 
(Gorlach et al., 2006; Malhotra and Kaufman, 2007). For these reasons, pyrazole was 
considered as a relevant oxidant stressor that affects redox status of ER and 
mitochondria: conditions that are suitable to address the objectives of this study.  
 
 
4.3 BIOCHEMICAL AND MOLECULAR BIOLOGY PROCEDURES 
 
 
4.3.1 Preparation of subcellular fractions 
 
Microsomes and mitochondria were isolated from fresh livers at 0-4
o
C as 
described by Genter et al (2006) with some modifications (Appendix 2). Mitoplasts 
fraction (mitochondria void of the outer membrane) was then further prepared from 
                                               
3 HeLa cells derived from human cervical cancer cells. 
4 Hepa1c1c7 cells derived from mouse liver hepatoma cells. 
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mitochondria by digitonin treatment. The microsomes and mitoplasts preparations were 
aliquoted and stored at -80
o
C until required. Protein concentrations of the microsomal 
and mitoplasts fractions were determined by the Lowry method (Lowry et al., 1951). The 
average protein concentrations of microsomal and mitoplasts fractions (BSA as standard) 
were 11.3 ± 1.04 µg/µl (3.4 ± 0.3 mg/g wet liver weight) and 7.8 ± 1 µg/µl (0.78 ± 0.09 
mg/g wet liver weight) respectively. 
 
 
4.3.2 Enzyme activity assays  
 
 
 NADPH Cytochrome P450 Reductase Activity 
 
NADPH-cytochrome P450 reductase (NPR) activity, a microsomal marker, was 
measured using an assay kit (Sigma-Aldrich, Sydney Australia), according to 
manufacturer’s instruction. NPR transfers electrons from NADPH to cytochrome C. The 
reduction of cytochrome C is monitored spectrophotometrically by the increase in 
absorbance at 550 nm. The rate of NPR activity in each sample was measured over 10 
minutes. The addition of potassium cyanide to the mitoplasts reaction mixture eliminates 
any contribution of COX to the activity. 
 
 
Cytochrome C Oxidase activity 
 
Cytochrome C oxidase (COX) activity, an inner mitochondrial membrane 
marker, was measured using an assay kit (Sigma-Aldrich, Sydney Australia), according 
to manufacturer’s instruction. Reduced cytochrome C is re-oxidised by COX. The 
decrease in absorbance at 550 nm in each samples was observed. 
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Haem oxygenase activity 
 
Haem oxygenase (HMOX) activity was measured by monitoring BR generation 
using the method previously described (Ryter et al., 2000). Incubation of 500 μl of 
reaction mixture
5
 was done in the dark at 37
o
C for 1 hour. The reaction was started by 
addition of substrate hemin (25 μM) and 1mM NADPH. The reaction was terminated by 
one volume of chloroform. The extracted BR was measured by difference in absorbance 
between 464 and 530 nm. BR concentration was calculated using ϵ (mM) of 40 cm-1 in 
chloroform. 
 
 
Biliverdin Reductase activity 
 
BVR activity was determined spectrophotometrically by monitoring the 
conversion of BV to BR. Assay conditions were carried out as previously described 
(Tenhunen et al., 1970; Ryter et al., 2000). Briefly, the reaction mixture
6
 was pre-
incubated for 5 minutes at 37
o
C. The reaction was started with substrate BV (25 μM) and 
100 µM NADPH. BR formation was monitored at 450 nm every 10 minutes for 1 hour. 
BR concentration was expressed as ρmol BR/mg protein/min using ϵ (mM) of 48.2 cm-1. 
 
 
Coumarin 7-hydroxylase activity 
 
Coumarin 7-hydroxylase (COH) activity was measured spectrofluorometrically 
by a modified method (Abu-Bakar et al., 2004) that was previously described (Burke and 
Mayer, 1974) using a final concentration of 0.1 mM coumarin. The detailed protocol is in 
Appendix 3. 
 
                                               
5 Containing 2mg/ml mouse cytosol, 1mM NADPH, 2 mM glucose 6-phosphate, 1 U glucose 6-phosphate 
dehydrogenase, 25 µM hemin, 0.25 M sucrose, 20 mM Tris-HCl, pH 7.4. 
 
6Containing 0.5mg/ml protein, 25 µM biliverdin, 100 µM NADPH and 0.1 M potassium phosphate buffer, 
pH 7.4. 
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In the enzyme kinetic study, treated mitoplasts fractions were incubated with 
various concentrations of substrate coumarin (0.5 μM to 50 μM) in the presence of 
increasing amounts of inhibitor BR (1.25 μM to 10 μM). This data was used to measure 
the enzyme velocity and to construct a Lineweaver–Burk plot to determine the type of 
inhibition BR presented. In all experiments, 50 μg of microsomes or mitoplasts proteins 
were used. 
 
 
4.3.3 Western blot 
 
The sodium dodecylsulfatepolyacrylamide gel electrophoresis (SDS-PAGE) 
technique was used to separate the proteins of interest by their molecular weight,  
followed by transferring the proteins onto PVDF membrane. Identification of specific 
protein was done by immunoblot analysis using mouse anti-HMOX1 monoclonal 
antibody, chicken anti-CYP2A5 monoclonal antibody, anti-goat polyclonal UGT1A1 
antibody, rabbit anti-NPR, anti-cytochrome oxidase IV (COX IV) ,  anti-cytochrome C 
and anti-BVR polyclonal antibodies. The antibody-antigen complexes were detected by 
chemiluminescent substrate. The protocol is detailed in Appendix 4. 
 
 
4.3.4 Bilirubin disappearance activity 
 
The rate of BR degradation by microsomes and mitoplasts was monitored by 
incubating BR with these fractions by a method described previously by Abu-Bakar et al 
(2005). The rate of BR oxidation is expressed as ρmol BR degradation/min/mg protein, 
using a ϵ (mM) of 48.2 cm-1. 
 
In the study of inhibitory effect of anti-CYP2A5 and anti-AdxR antibodies on 
BR degradation, the final concentration of microsomal or mitoplasts proteins used were 
50 μg.  Increasing concentrations of antibodies were added at the same time as 10 μM BR 
(in dimethyl sulfoxide (DMSO)) to obtain concentration ratios to proteins ranging from 
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approximately 0.0005 to 2.0. Inhibited BR oxidation rate in the presence of antibodies 
against uninhibited rate was calculated to determine the remaining percentage of BR 
oxidation rate. To study the contribution of ROS towards BR disappearance, the same 
condition was employed with different concentrations of ascorbic acid (ranging from 2 
mM to 200 mM).  
 
 
4.4 SCREENING OF BILIRUBIN OXIDATIVE METABOLITES 
(BOMs) 
 
 
 4.4.1 HPLC/MS-MS analysis of BOMs 
 
 
Metabolites screening was performed as previously described (Abu-Bakar et al., 
2011; Arthur et al., 2012). The reaction mixtures were incubated for 1 hour in the dark at 
37
o
C after which samples were filtered using 0.45 µm filter membrane. For positive 
control, in vitro oxidation of BR was generated by incubating BR with Fe-EDTA/H2O2 
for 1 hour. These mixtures were immediately injected to a HPLC-MS/MS (ABSciex 
QTrap 5500 mass spectrometer, USA) equipped with an electrospray  (Turbo V) 
interface coupled to a HPLC system (Nexera, Shimadzu Corp., Kyoto, Japan). Separation 
was achieved using a 2.5 micron 50 x 2 mm Synergi MAX RP column (Phenomenex, 
Torrance, CA, USA) run at 40
o
C, and mobile phase flow rate of 0.5 mL/minute with a 
linear gradient starting at 5% B for 1.0 minute, ramped to 80% B in 10 minutes, held for 
1 minute, to 5% B in 0.2 minute and equilibrated for 3 minutes (mobile phase A = 1% 
acetonitrile / HPLC grade water, mobile phase B = 95 % acetonitrile / HPLC grade water, 
both containing 5 mM ammonium acetate). The mass spectrometer was operated in the 
positive ion, multiple reactions monitoring mode using nitrogen as the collision gas under 
the following conditions: declustering potential was 75 or 110 (BV only), and the 
collision energy was between 25-83 eV. HPLC/MS-MS conditions are detailed in 
Appendix 5 and Appendix 6. The percentages of screened metabolites were calculated 
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based on the intensity of 10 μM BR at zero incubation time. The relative amounts of each 
dipyrroles were determined using area under curve (cps) data. 
 
 
4.5 STATISTICAL ANALYSIS 
 
 
Analysis of the enzyme kinetic parameters was determined by GraphPad Prism 
5 kinetics programme from GraphPad Software Inc (La Jolla, CA, USA). It uses a non-
linear regression method of curve and the runs test of residuals to determine statistically 
whether experimental data are randomly distributed around the curve with 95% 
confidence. The programme calculates Ki by plotting observed Km (Y-axis) vs BR 
concentrations (X-axis). For data other than enzyme kinetic parameters Student’s t-test 
was used for comparisons between two groups. Mean differences were considered 
significant when p < 0.05. 
 
 34 
 
5.     RESULTS AND DISCUSSION 
 
 
5.1 Purity of Microsomal and Mitoplasts Fractions 
 
 
The purity of the microsomal and mitoplasts fractions was assessed by 
measuring the presence of cytochrome C oxidase IV (COX IV) and NADPH P450 
reductase (NPR): markers of mitochondrial inner membrane (IMM) and ER respectively. 
Western immunoblotting showed that a minimal amount of NPR was present in the 
mitoplasts (Figure 5.1A), which commensurate with the NPR activity (approximately 
10% of the activity in microsomes) (Figure 5.1B). This suggests that nearly all of the ER 
associated with mitochondria has been removed.  
 
On the other hand, no COX IV-reactive band was found in the microsomal 
fraction although a minimal decrease in absorbance of 550 nm (2-4% of mitoplasts 
activity) was detected, possibly due to unspecific reaction or normal fluctuation. This 
suggests a high microsomal enrichment with only minor mitochondrial contamination. 
Subsequent data analysis was adjusted against the 10% microsomal contamination and 
2% to 4% mitoplasts contamination when relevant. It is noted that the COX activity in 
the treated mitoplasts was significantly reduced to about 25% of control mitoplasts. 
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(A) 
Microsomes            Mitoplasts 
   
     
μg protein/well     2  4   2  4 2          4             2          4          + 
 
                                          
 
(B) 
 
 
Figure 5.1 Evaluation of purity of microsomal and mitoplasts isolation using subcellular 
enzymes markers. Male DBA/2J mice were given normal saline (control group) or 200 mg 
pyrazole/kg body weight for 3 consecutive days (treated group). (A) Western blot analysis of NADPH 
P450 reductase (NPR) and cytochrome C oxidase IV (COX IV) proteins of microsomes and 
mitoplasts fractions isolated from control and pyrazole treated mice. Positive control (+) = NPR and 
COX IV peptides. (B) NPR and COX IV activities in liver microsomes and mitoplasts from and 
pyrazole-treated mice. Results are given as means ± SD of three separate observations (n=3). 
*Significant different from control group, p < 0.05 (Student t-test). 
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5.2 Bilirubin Metabolising Enzymes in Mitochondria 
 
 
5.2.1 Effects of Pyrazole on HMOX1 and CYP2A5 Protein Expression 
 
Pyrazole treatment substantially increased HMOX1 and CYP2A5 
immunoreactive bands in microsomes and mitoplasts (Figure 5.2). The intensities of 
respective bands were consistent with the amount of protein loaded in each well (Figure 
5.2A).  
 
Compared to controls, HMOX1 induction in the microsomes was greater than 
that of CYP2A5 (6-fold for HMOX1 and 3-fold for CYP2A5) (Figure 5.2B). The 
opposite was observed in mitoplasts where HMOX1 induction was about 2-fold less than 
the CYP2A5 induction (Figure 5.2B).  
 
 
A)  
       Microsomes                           Mitoplasts 
     
       
μg protein/well          5       10         5           10             5         10             5          10          +    
 
            
 
 
           
 
 
 
             control         treated              control       treated 
    
HMOX1 
32 kDa 
CYP2A5 
50 kDa 
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 B) 
 
 
 
Figure 5.2 Effects of pyrazole treatment on HMOX1 and CYP2A5 protein expression in liver of 
DBA/2J mice A) Western blot analysis of HMOX1 and CYP2A5 proteins in microsomes and 
mitoplasts from livers of control and pyrazole-treated mice. HMOX1 peptide and recombinant yeast 
microsomes were used as positive controls (+) for HMOX1 and CYP2A5, respectively. B) 
Densitometric analysis of 10 µg of HMOX1 and CYP2A5 blots. Results are given as means ± SD of 
three separate observations (n=3). * Significant different from control group, p < 0.05 (Student t-test). 
 
 
Although HMOX1 protein induction in mitoplasts was three times less than in 
microsomes (Figure 5.2B), the increment in catalytic activity of this enzyme was similar 
in both organelles (increased by 4-fold compared to control) (Table 5.1). This may 
suggest differences in the reactivity of anti-HMOX1 antibody vis-à-vis the mitochondrial 
and microsomal HMOX1.  
 
On the other hand, the strong induction of microsomal and mitochondrial 
CYP2A5 protein was reflected in the CYP2A5-catalysed coumarin 7-hydroxylase (COH) 
activity 10-fold and 60-fold increase, respectively (Table 5.1). 
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Table 5.1 Haem oxygenase (HMOX), biliverdin reductase (BVR) and coumarin 7-hydroxylase 
(COH) activities of liver cytosol, microsomes and mitoplasts from DBA/2J mice. Mice were either 
untreated controls or were treated with 200 mg pyrazole/kg body weight for 3 consecutive days. 
Results are given as means ± SD of three separate observations (n=3).  
#   
ρmol umbelliferone/min/mg protein 
## 
ρmol BR/min/mg protein 
* p < 0.05, compared with corresponding values of un-induced fractions.  
 
 
Pyrazole is known to induce oxidative liver injury in Nrf2 deficient mice (Lu et 
al., 2008). It is also known that pyrazole-induced microsomal HMOX1 and CYP2A5 are 
associated with elevated Nrf2 in the liver (Lu et al., 2008). Furthermore, Gilmore and 
Kirby, (2004) reported that induction of CYP2A5 by pyrazole is a consequense of ER 
stress. These published data together with previous observations that HMOX1 and 
CYP2A5 expressions are regulated by Nrf2 (Alam et al., 1999; Abu-Bakar et al., 2007) 
strongly suggest that the changes in CYP2A5 and HMOX1 expressions in mitoplasts and 
microsomes observed in the present study are caused by pyrazole-induced ER oxidative  
stress.  
 
Given that haem is the substrate for HMOX, induction of this enzyme by 
pyrazole would result in depletion of cellular haem pool. This, could in turn, affect the 
activity of haemoproteins, such as CYP enzymes and mitochondrial COX. However, this 
is the opposite of what I observed with regard to CYP2A5 activity. Elevation of COH 
activity indicates a complete incorporation of limited free haem into the CYP2A5 
Enzyme 
Activity 
 
    
Cytosol Microsomes Mitoplasts 
None Pyrazole   None  Pyrazole None Pyrazole 
 
COH
#
 
 
ND 
 
ND 
 
743 ± 99 
 
7329 ± 500
*
 
 
10 ± 0.5 
 
622 ± 53
*
 
 
HMOX
##
 
 
ND 
 
ND 
 
260 ± 23 
 
964 ± 63
*
 
 
83 ± 10 
 
295 ± 30
*
 
 
BVR
##
 
 
30 ± 2.5 
 
36 ± 10 
 
ND 
 
      ND 
 
23.8 ± 4.5 
 
44.6 ± 1
*
 
 39 
 
apoprotein. This therefore indicates preferential haem incorporation into CYP2A5 
apoprotein, as it has been acknowledged that induction of HMOX1 by any form of 
oxidative stress is associated with reduction in total CYP activity, and that CYP2A5 is 
the only CYP form that is induced under this condition (Beri and Chandra, 1993; Seubert 
et al., 2002; Abu-Bakar et al., 2004). These observations support the hypothesis that 
CYP2A5 maybe differently regulated compared to other CYP enzymes, and have a role 
in cytoprotection against oxidative damage. 
 
As expected, the activity of mitochondrial COX was significantly reduced by 
pyrazole treatment (Figure 5.1B). This could be explained, in part, by the fact that the 
mitochondrial haem content is limited (Converso et al., 2006). The activities of both 
HMOX2 and HMOX1 during oxidative stress (Agarwal and Nick, 2000; Converso et al., 
2006) could impact on the limited mitochondrial haem availability and consequently 
reduce the COX activity, which in turn may negatively affect mitochondrial respiration, 
increase local ROS and contribute to membrane damage. 
 
These results suggest that the BR production and oxidation enzymes are targeted 
to mitochondria in response to pyrazole-induced ER oxidative stress. To further 
characterise the microsomal and mitochondrial BR metabolic systems, BVR and 
UGT1A1 protein levels were determined in the respective organelles. 
 
 
5.2.2 Effects of pyrazole on BVR and UGT1A1 expression 
   
 
The activity of cytosolic BVR, an enzyme that catalyses the reduction of BV to 
BR, was insignificantly affected by pyrazole treatment, although the protein expression 
was down regulated to about 60% of the control levels. By contrast, BVR protein levels 
in the treated mitoplasts increased by about 32% of control (Figure 5.3). The elevated 
protein levels corresponds well with the enzyme activity, where the induction was about 
2-fold in treated mitoplasts (Table 5.1). Additionally, no BVR protein was detected in 
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both microsomal fractions which further confirm high microsomal enrichment, as shown 
in section 5.1. 
 
A)  
           Cytosol                    Microsomes             Mitoplasts 
 
     
 
 
 
    
B) 
 
 
 
Figure 5.3 Effect of pyrazole treatment on BVR protein expression in the liver of DBA/2J mice. 
(A) Western blot analysis of BVR protein in cytosol, microsomes and mitoplasts from livers of 
control and pyrazole-treated mice. BVR peptide was used as a positive control (+). (B) Densitometric 
analysis of 20 µg of BVR blots. The means ± SD are of three separate observations (n=3).  
* Significant different from control group, p < 0.05 (Student t-test). 
0
500000
1000000
1500000
2000000
2500000
cytosol microsomes mitoplasts
control
treated
B
A
N
D
 D
EN
SI
TY
 (
ar
b
it
ra
ry
 v
al
u
es
) 
* 
              control       treated      control      treated     control     treated  
 μg protein/well    10      20      10       20     10     20     10   20     10      20      10       20       +    
 
 
       
BVR  
33 kDa 
 41 
 
By contrast, pyrazole totally repressed the expression of UGT1A1 in 
microsomes, suggesting that BR conjugation does not take place during ER stress (Figure 
5.4).  UGT1A1 protein was not detected in mitoplasts (Figure 5.4), confirming previous 
observation that UGT enzymes are not known to be present in the mitochondria 
(Radominska-Pandya et al., 2005). 
 
 
            Microsomes                             Mitoplasts      
 
       
     
  
 
 
Figure 5.4 Effect of pyrazole on UGT1A1 protein expression. Western blot analysis of microsomal 
and mitoplasts proteins from livers of control and pyrazole-treated DBA/2J mice probed with anti-
UGT1A1 antibody. UGT1A1 peptide was used as a positive control (+).  
 
 
As UGT1A1 is the sole enzyme that catalyses glucuronidation of BR, the 
present observations indicate that BR was not glucuronidated when the ER is under 
stress. This result supports the assumption that UGT1A1 may not be involved in 
regulating minute intracellular levels of BR, but rather important in the clearance of 
excessive amounts of BR from systemic circulation (McDonagh, 2010). The absence of 
this pathway in mitochondria further emphasise the importance of BR oxidation in 
managing intracellular BR. 
 
Importantly, the evidence of recruitment of HMOX1 and BVR in mitochondria 
(Figure 5.2, 5.3 and Table 5.1), indicates heightened local BR production in response to 
oxidative stress. Because mitochondria are particularly sensitive to high BR 
concentrations that can eventually lead to apoptosis, the presence of CYP2A5 could 
                        control         treated                control        treated    
        μg protein/well       5          10          5          10             5           10          5        10        +    
         
UGT1A1 
53 kDa 
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suggest that the local BR is maintained within safe levels by converting to nontoxic BV, 
possibly to be used when required (as discussed in section 2.2.2).  However, the capacity 
of mitochondrial CYP2A5 to oxidise BR is not known and is addressed in the next 
section.  
 
5.3 Bilirubin Degradation in Mitochondria  
 
It has been established that the CYP2A5-dependent BR oxidation exists in 
microsomes and that the activity is substantially increased in response to chemical-
induced oxidative stress (Abu-Bakar et al., 2005). In exploring the existence of this 
system in mitochondria and its inducibility in response to oxidative stress, BR 
degradation rate was initially measured spectrometrically in incubations with mitoplasts 
and microsomes. Table 5.2 shows that BR disappeared in the presence of control 
microsomes and mitoplasts, and that the disappearance rate increased in pyrazole-treated 
microsomes and mitoplasts. Interestingly, the rate in control microsomes and mitoplasts 
is about the same, but in treated microsomes it increased three times more than in treated 
mitoplasts (3-fold increase in treated microsomes; 1.7-fold increase in mitoplasts) (Table 
5.2). The observations suggest that while a BR oxidation system exists in both organelles 
it differs in the kinetics of inducibility. 
 
 
Table 5.2 Bilirubin degrading activity in liver microsomes and mitoplasts of DBA/2J mice. Mice 
were either untreated controls or were treated with 200 mg pyrazole/kg body weight for 3 consecutive 
days. Hepatic microsomal and mitoplasts fractions were isolated for the estimation of bilirubin 
degrading activities.   Results are given as means ± SD of three separate observations (n=3).  
 
 
 
 
 
#ρmol BR/min/mg protein   
*p < 0.05, compared with corresponding values of un-induced fractions.            
                                    
Enzyme Activity         MICROSOMES          MITOPLASTS 
           None        Pyrazole                       None          Pyrazole 
Bilirubin degradation rate
# 
       1175 ± 30       3783 ± 259*                940 ± 85       1580 ± 70* 
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It is known that in the microsomes, BR is subjected to random oxidation by 
ROS and to specific oxidation by mouse CYP2A5 and human CYP2A6 enzymes (De 
Matteis et al., 2006; Abu-Bakar et al., 2011; Abu-Bakar et al., 2012; Jansen and Daiber, 
2012). The non-enzymatic oxidation of BR predominantly generates smaller metabolites, 
dipyrroles (De Matteis et al., 2006; Abu-Bakar et al., 2011), while the predominant 
product of enzymatic oxidation is BV (Abu-Bakar et al., 2011). As mitochondria are the 
major producers of intracellular ROS through leakage of their electron transfer system, it 
is thus plausible that the observed BR disappearance activity may be caused by both 
enzymatic and non-enzymatic oxidations. 
 
 
5.3.1 Contribution of ROS to bilirubin degrading activity  
 
 
To explore the possibility that ROS may be involved in the oxidation of BR, 
incubations of microsomal and mitoplasts fractions were done in the presence of ascorbic 
acid — a ROS scavenger — to exclude random oxidation by ROS (Zhao et al., 1990; 
Meister, 1992; Tsai et al., 2007).  Accordingly, 200mM ascorbic acid was used in all 
reactions. This concentration has been shown to effectively inhibit BR oxidation by ROS 
(see Appendix 7). 
 
Ascorbic acid did not significantly inhibit BR degradation in control 
microsomes but inhibited about 22% of the reaction in pyrazole-treated microsomes 
(Figure 5.5). This suggests that random oxidation of BR by ROS is a minor event in 
microsomes and most of the disappearance (about 78%) is catalysed by some other 
mechanism, most likely CYP2A5.  
 
By contrast, ROS-driven BR disappearance seems to be the major, if not the 
only degradation pathway in the control mitoplasts, as 100% of the BR disappearance 
was blocked by ascorbic acid (Figure 5.5). In the treated mitoplasts however, only 54% 
of BR degradation was blocked by ascorbic acid (Figure 5.5), further suggesting that in 
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response to oxidative stress another pathway of BR degradation, independent of ROS, is 
as important as the ROS-mediated oxidation. 
 
In addition, these results seem to suggest that there is a correlation between the 
CYP2A5 catalysed COH activity and the BR disappearance rate: whenever the COH 
activity is low, the relative contribution of the ROS to BR degradation seems to be high. 
In extreme case, in the control mitoplasts, where the COH activity was absent, the 
ascorbic acid blocked BR disappearance was 100%. Conversely, when the COH activity 
is increased, the proportion of ROS-driven BR oxidation is decreased. 
 
Why the ROS-driven BR oxidation proportionally increased in microsomes 
despite the strong increased of the COH activity? This is not known but one could 
speculate that pyrazole treatment leads to disintegration of the membrane structure and 
increase leakage of ROS from the monooxygenase complex. 
 
In the case of untreated mitoplasts, it could be that ROS is an inherent by-
product of the electron transport chain which could explain the un-enzymatic oxidation 
of BR.  
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Figure 5.5 Effect of  200mM ascorbic acid on bilirubin (BR) degradation activity in liver 
microsomes and mitoplasts of DBA/2J mice. Mice were either untreated controls or were treated 
with 200 mg/kg body weight of pyrazole for 3 consecutive days. Hepatic microsomal and mitoplasts 
fractions were isolated for the estimation BR degradation activities. Results are given as means ± SD 
of three separate observations (n=3). * Significant different from control group, p < 0.05 (Student t-
test). 
 
 
5.3.2 Contribution of CYP2A5 to bilirubin degrading activity 
 
  
To explore the relative contribution of CYP2A5 to BR oxidation in both 
organelles, studies with antibody directed against microsomal CYP2A5 were undertaken. 
It is known that this antibody can recognise its mitochondrial counterpart (Honkakoski et 
al., 1988).  
 
The results show that increased concentrations of anti-CYP2A5 antibody were 
able to gradually inhibited BR disappearance. The maximum inhibitory effect was strong, 
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about 70% in both control and pyrazole-treated microsomes, respectively (Figure 5.6). 
The amount of CYP2A5 antibody needed to achieve maximum inhibition in treated 
microsomes was about 13-fold higher than needed in control fraction, indicating that 
larger amounts of CYP2A5 protein responsible for BR disappearance were present in this 
sample, in conformity with Western blot analysis  and the COH activity (Figure 5.2 and 
Table 5.1).  
 
As expected, a significant inhibition of about 55% could be reached in mitoplasts 
only after pyrazole treatment. This correlates well with the results of ascorbic acid 
incubation, whereby the inhibition was about 54% (Figure 5.5), and taken together this 
amounts to about 100% of BR oxidation. On the contrary, no significant inhibition could 
be seen in the control mitoplasts with only some non-dose response inhibition taking 
place,   implying the CYP2A5 catalysed BR oxidation in this fraction is insignificant. By 
contrast, these results suggest that BR oxidation in treated mitoplasts is almost equally 
driven by CYP2A5 and ROS. 
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Figure 5.6 Effect of anti-CYP2A5 antibody on bilirubin (BR) degradation activity of control and 
pyrazole-treated microsomes and mitoplasts fractions. The antibody was added in increasing 
amount so as to achieve the antibody to microsomal or mitoplasts protein concentrations indicated. In 
all fractions, 10 μM final concentration of BR was used. BR-degrading activity is expressed as a 
percentage of the corresponding values. Results are given as means ± SD of three separate 
observations (n=3).  
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To confirm that the enzymatic BR oxidation is catalysed by the respective 
monooxygenase complexes in each organelle, anti-adrenodoxin reductase (AdxR) 
antibody was added to the incubation mixtures. AdxR, is a key component of the 
mitochondrial monooxygenase system that provides electrons to the mitochondrial CYP 
catalysed reactions and is absent in microsomes.  
 
Figure 5.7 shows that the antibody did not inhibit microsomal BR 
disappearances, suggesting that the microsomes are essentially free from mitoplast 
contamination (further confirming data presented in section 5.1), and confirming that the 
microsomal BR degradation is essentially driven by the microsomal monooxygenase 
system. 
 
By contrast, the anti-AdxR antibody inhibited BR degradation by 50% in treated 
mitoplasts but not at all in control mitoplasts (Figure 5.7). This result is in agreement 
with the results in section 5.3.1 and Figure 5.6, and confirms that in control mitoplasts 
BR disappearance is predominantly driven by ROS-mediated oxidation and that in 
treated mitoplasts the metabolism is driven 50% by mitochondrial CYP2A5. 
Furthermore, this result also confirms the purity of microsomal fractions with least 
contamination from mitochondria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
(A) 
 
 
(B) 
 
 
Figure 5.7 Effect of anti-adrenodoxin reductase (AdxR) antibody on bilirubin (BR) degradation 
activity in microsomes and mitoplasts fractions. Inhibition of BR degrading activity of (A) control 
and pyrazole-treated microsomes (B) control and pyrazole-treated mitoplasts, by anti-adrenodoxin 
reductase antibody.The antibody was added in increasing amounts so as to achieve the antibody to 
microsomal or mitoplasts protein concentrations indicated. In both (A) and (B) 10 μM final 
concentration of BR was used. BR-degrading activity is expressed as a percentage of the 
corresponding values. Results are given as means ± SD of three separate observations (n=3).  
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 It is pertinent to confirm these observations by screening the metabolites profile 
of BR oxidation. As BV is the predominant metabolite of CYP2A5-driven BR oxidation 
and dipyrroles are the major products of BR scavenging ROS, it  is anticipated that the 
conditions in the treated  microsomes would favour more BV than dipyrroles production 
due to high CYP2A5 expression, whilst dipyrroles would be the main metabolites 
produced in untreated mitoplasts, with increasing BV production when treated with 
pyrazole,  due to induced CYP2A5 . 
 
After one hour incubation, almost 100% BR was lost in the chemical oxidation 
(driven solely by ROS scavenging). The microsomal and mitoplasts system was 
comparatively equally efficient at BR oxidation, but less so than the chemical oxidation 
system (Figure 5.8). An average of 49% and 59% loss of BR in control and pyrazole-
treated microsomes was observed respectively. The most significant difference between 
either incubations of microsomal and mitoplasts with chemical oxidation was in the level 
of BV produced.  
 
 No BV formation but only dipyrroles products were observed in the chemical 
oxidation system, confirming previous findings that dipyrroles are the major products of 
non-enzymatic BR-oxidation (De Matteis et al., 2006; Abu-Bakar et al., 2011; Abu-
Bakar et al., 2012).  The highest levels of BV proportionally to dipyrroles were produced 
by untreated microsomes followed by treated microsomes. On the other hand, most 
dipyrroles relative to BV was produced by control mitoplasts followed by treated 
mitoplasts (Figure 5.8). These results are in accordance with ascorbic acid inhibition 
studies (Chapter 5.3.1) as well as with studies using CYP2A5 antibody (Figure 5.6). The 
small amounts of dipyrroles showed in control microsomes and BV showed in control 
mitoplasts are potentially artefacts, i.e., marginal side products of unspecific reactions 
(De Matteis et al., 2006). 
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Figure 5.8 Summary of the oxidative products of bilirubin (BR) formed in the chemical and 
enzymic systems. Oxidative products formed in each of the systems are expressed as a percentage of 
the intensity of  initial BR concentration. Results are given as means ± SD of three separate 
observations (n=3). *Significant different from control group, p < 0.05 (Student t-test). 
 
 
Additionally, break down products of non-enzymatic microsomal BR oxidation 
were compared with those of mitochondria. Three smaller products (ions m/z 301,315 
and 333) were identified in the BR oxidations of microsomes and mitoplasts as 
previously reported (De Matteis et al., 2006; Abu-Bakar et al., 2011; Arthur et al., 2012). 
The relative amount of each BOM product in the control and pyrazole-treated 
microsomes and mitoplasts are depicted in Figure 5.9. The major BOM in both cases was 
ion m/z 301, although almost as much of ion m/z 315 was formed in mitoplasts. The 
levels of these ions were increased after pyrazole exposure. According to Arthur et al 
(2012), the more hydrophilic dipyrrole (ion m/z 301) is predominantly produced, possibly 
to assist the excretion, as seen in urinary BOMs of oxidative stressed mice. 
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It has been purported that these BOMs result from the cleavage of BR central 
methylene bridge by ROS that give rise to BR peroxyradical (De Matteis et al., 2006; 
Abu-Bakar et al., 2012), which can then disintegrate into ions m/z 315 and 301. It is 
suggested that a relatively stable ion m/z 333 could be further formed when ion m/z 315 
encounter hydroxyl radical (personal communication) (see Figure 1 in Appendix 7). As 
reviewed in Chapter 2.1.1, mitochondria are the primary source of ROS, which can be 
aggravated during oxidative stress. Thus, the higher level of ion m/z 333 in treated 
mitoplasts as compared to microsomes could owe to the increased ROS availability in 
this organelle. 
 
 
 
 
Figure 5.9 Effect of pyrazole on microsomal and mitoplasts BOMs. Relative amounts of each BOM 
formed in control and pyrazole-treated microsomes  and mitoplasts were determined using area under the 
curve data obtained from HPLC/MS-MS. Results are given as means ± SD of three separate 
observations (n=3). * Significant different from control group, p < 0.05 (Student t-test). 
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5.3.3 Microsomal and mitochondrial CYP2A5 enzymes have similar affinity to 
bilirubin 
 
 
It has been shown that both microsomal and mitochondrial CYP2A5 enzymes 
have a high affinity towards coumarin. Thus, coumarin can be used as diagnostic 
substrate for these enzymes (Honkakoski et al., 1988). To further characterize the 
interaction of BR with mitochondrial CYP2A5, 7-hydroxylation of coumarin in treated 
mitoplasts was inhibited with different concentrations of BR.  
 
Figure 5.10A shows that the formation of 7-hydroxycoumarin by mitoplasts 
CYP2A5 followed simple Michaelis-Menten kinetics. Inhibition of mitochondrial 
coumarin 7-hydroxylation by BR is of a mixed type that affected both the Vmax and Km, 
where the Vmax is slightly reduced and the Km is increased. The Km was 6.14 ± 0.5 μM, 
which is 13 times more than that of microsomes, suggesting that coumarin affinity to the 
mitochondrial CYP2A5 is a lot less than to the microsomal CYP2A5 (Figure 5.10B). 
This aligns with previous observations that targeted CYPs are modified to depend on 
mitochondrial ETC for a supply of electrons for catalytic activity toward altered substrate 
specificity/affinity (reviewed by Kinonen et al., 1995). This in turn may explain the odd 
correlation between changes of mitochondrial COH activity and the corresponding 
mitochondrial CYP2A5 protein levels observed in section 5.2.1, Figure 5.2 and Table 
5.1. 
 
The plot Km observed vs BR concentrations (Figure 5.10B) yielded a linear graph, 
which confirmed the competitiveness of BR inhibition to the reaction with Ki = 2.67μM. 
This indicates that BR affinity for mitochondrial CYP2A5 is as high as the reported 
affinity for  microsomal enzyme (ranging from 0. 7 to 2.2 μM) and comparable to 
coumarin affinity for microsomal CYP2A5 (ranging from 0.5 to 2.0 μM) (Kinonen et al., 
1995; Draper et al., 1997; Abu-Bakar et al., 2005; Abu-Bakar et al., 2012). Importantly, 
BR affinity for mitochondrial/microsomal CYP2A5 (0.5-2.7 μM) appears therefore to be 
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similar (unlike that of coumarin) and optimal for maintaining the intracellular BR 
concentrations at sub-toxic levels of <10 μM.   
 
 According to Genter et al (2006), protein secondary structure of microsomal 
CYP2A5 is altered to allow mitochondrial targeting, as well as integration into 
mitochondrial monooxygenase-electron transfer system, although this would not be 
expected to alter its function. As a result, mitochondrial enzymes can show changes in 
substrate specificity (Kinonen et al., 1995; Sangar et al., 2010). This could then affect the 
accuracy of coumarin-CYP2A5 docking. It would seem that the interaction of BR-
CYP2A5 was not affected by this, perhaps due to dissimilar active site. Indeed, docking 
analysis of CYP2A6 protein (the human orthologue of CYP2A5) has been analysed 
previously to simulate molecular docking of BR and coumarin on the CYP2A6’s active 
site. Both interact with a few amino acid residues: BR forming hydrogen bond at Asn297 
and Thr305, while coumarin with Asn297, as well as a few phenylalanine residues (Abu-
Bakar et al., 2012; Abu-Bakar et al., 2013). Additionally, considering the nature of BR 
that has a large structure, it is also plausible that the binding of BR to CYP2A5 would 
hinder the coumarin-CYP2A5 interaction. Thus, it would be interesting to predict the 
coumarin and BR mitochondrial CYP2A5 binding site to confirm these results. 
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(A) 
 
 
[BR] μM 
 
Vmax  
(ρmol/mg protein/min) 
Km Observed  
(µM coumarin) 
0 711 ± 21 6.8 ± 0.5 
1.25 688 ± 40 7.5 ± 1.0 
2.5 665 ± 34 12.48 ± 1.4 
10 601 ± 23 14.9 ± 1.2 
 
(B) 
 
 
Figure 5.10 Effect of bilirubin (BR) on coumarin 7-hydroxylase activity in pyrazole-treated 
mitoplasts. (A) Mitoplasts was incubated with various concentrations of coumarin with increasing 
amounts of BR. The rates of 7-hydroxylation were measured fluorometrically. The Km value for coumarin 
7-hydroxylation was 6.14 ± 0.5 μM. BR increased the Km and slightly reduced the Vmax. (B) Km observed 
vs BR concentrations plot indicates that BR is a competitive inhibitor with Ki = 2.67 μM.  
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5.3.4 Effect of pyrazole on the release of cytochrome C from mitochondria 
 
 
Cytochrome C is a protein bound to inner mitochondrial membrane and    can be 
released when the membrane is damaged. Cytochrome C release is a pre-requisite 
condition for apoptosis and can be initiated by oxidative stress (Srinivasan and Avadhani, 
2012).  Analysis of this protein in mitoplasts and cytosol will give a glimpse on the 
extent of damage in this organelle; whether or not pyrazole treatment caused any damage 
on mitochondrial membrane. The result shows that cytochrome C was not detected in the 
cytosolic fractions of either group. On the other hand, mitoplasts fractions showed 
substantial accumulation, with no significant difference between the two groups (Figure 
5.11). This suggests that the mitochondrial membrane is intact, and that the organelles 
are not damaged.  
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A)                                     Cytosol          Mitoplasts 
 
 
 
 
 
 
 
B) 
 
 
 
 
Figure 5.11 Effect of pyrazole on cytochrome C protein expression. (A) Western blot analysis of  
cytosolic and mitoplasts proteins from livers of control and pyrazole-treated DBA/2J mice probed 
with anti-cytochrome C antibody. Cytochrome C peptide was used as a positive control (+). (B) 
Densitometric analysis of 30 µg of cytochrome C blots. The means ± SD are of three separate 
observations (n=3).  
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It has been suggested that reduction of mitochondrial COX level is accompanied 
by release of cytochrome C into cytosol (Sanchez-Alcazar et al., 2000). This is in 
contrast to the present results (Figure 5.1 and Figure 5.11). This could be due to:  
 
1) methodological limitations: whether the cytochrome C antibody applied in 
the Western blotting was enough to detect low levels of cytochrome C released into 
cytosol. Thus, it would be interesting to employ a more sensitive technique such as 
immunoelectron microscopy to study the microstructure in mitochondria and detect 
apoptotic proteins; or 
 
2) mitochondrial integrity was uncompromised and apoptotic signals were not 
amplified due to increased antioxidant capacity via recruitment of the HMOX1 / 
CYP2A5 antioxidative system. The results suggest that although with limited COX 
activity, the mitochondria were not overly stressed so as to initiate apoptosis. Previous 
findings have shown that despite a strong correlation between upregulated CYP2A5 and 
hepatocellular damage, and that some CYP2A5 inducers are pro-apoptotic (Habeebu et 
al., 1998; Shi et al., 1998), no link between CYP2A5 build-up and apoptosis can be 
established.  Recently, CYP2A5 overexpression has been shown to confer cytoprotection 
against BR-induced apoptosis (Kim et al., 2013), which is in accordance with the current 
result. It is likely that the cells are in damage control mode and that local ATP pool in 
mitochondria and in ER may be dedicated to importing necessary cytoprotective proteins, 
as reflected in the changed activities of BR regulating enzymes in microsomes as well as 
in mitochondria. Additionally, HMOX1 catabolism product, CO can bind to COX. Such 
binding would also supress COX activity, which in turn may degrade pro-apoptotic 
pathway that prevents mitochondrial membrane permeability and apoptosis (Gozzelino et 
al., 2010; Queiroga et al., 2011).  
 
It has been shown that mitochondria defects (increasing ROS levels and 
decreasing ATP levels) can regulate adenine monophosphate-activated protein-activated 
kinase (AMPK) and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-
1α) (Adom and Nie, 2013), that are important in energy homeostasis and liver functions 
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(Yang et al., 2010; Liu and Lin, 2011).  These inductions can lead to ROS 
detoxifications, promotion of catabolic pathway such as glycolysis to maintain ATP, as 
well as mitochondrial biogenesis to increase mitochondrial content and activity that 
would allow tissue adaptation to stress. Additionally, defective mitochondria can be 
eliminated by mitophagy through AMPK pathway, to protect cells from apoptosis 
(Nadege et al., 2009; Liu and Lin, 2011; Wu and Wei, 2012; Adom and Nie, 2013).  
 
Therefore, it is of particular interest that pyrazole treatment is associated with 
hepatic glycogen depletion and that CYP2A5 can be induced by fasting and glucagon 
(hormone that promotes breakdown of glycogen) through PGC-1α. (Arpiainen et al., 
2008; Nichols and Kirby, 2008; Abu-Bakar et al., 2013). Nevertheless, the PGC-1α-
CYP2A5 induction is thought to prevent BR cytotoxicity as fasting can upregulates 
serum BR levels whilst the reduced hepatic glycogen content would be due to increased 
glucose 6-phosphate production through glycogenolysis to replenish NADPH. NADPH 
in turn is used to regenerate GSH (Gilmore et al., 2003; Kirby et al., 2011), which is 
important in protecting water soluble proteins from oxidative damage (Sedlak et al., 
2009).   Then again, inhibition of AMPK during pyrazole intoxication has been shown to 
downregulate CYP2A5 mRNA expression (reviewed by Kirby et al., 2011). Given the 
role of AMPK and PGC-1α in maintaining cellular energy homeostasis, mitochondrial 
generation and liver functions, could it be possible that their interactions with CYP2A5 
are also in part to restore ATP homeostasis, whilst cells are geared towards combating 
oxidative damage? Indeed, it would be attractive to consider a few synchronised damage 
control mechanism regulated by CYP2A5 to restore BR and energy homeostasis, as 
depicted in Figure 5.12. 
 
 
5.4 CONCLUSIONS 
 
It has been shown that mitochondria are particularly sensitive to oxidative stress 
and local antioxidant capacity including the BR is needed to be present to protect its 
structures against ROS. On the other hand, high BR concentrations can also be toxic and 
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can eventually lead to apoptosis (Rodrigues et al., 2002; Malik et al., 2010). As has been 
shown (Figure 5.2 and 5.3, Table 5.1), critical BR producing enzymes, HMOX1 and 
BVR are targeted to mitochondria during pyrazole-induced oxidative stress. However, it 
is not known how mitochondria are protected against high BR levels.  Mitochondrial BR 
oxidase has been previously proposed yet never been confirmed. My initial results clearly 
demonstrate the recruitment of mitochondrial CYP2A5 under oxidative stress conditions 
(Figure 5.2 and Table 5.1). However, its role in this organelle, let alone pertaining to BR 
metabolism is unknown. 
 
It would seem that the microsomal defence system alone is insufficient to 
manage intracellular oxidative stress but needs to be recruited into mitochondria too. In 
response to pyrazole-induced ER stress, the enzymes crucial in regulating BR were 
recruited into mitochondria, which indicate increased local BR production capacity and 
elevated BR levels, which in turn could damage mitochondrial membrane. Nevertheless,  
the UGT1A1 enzyme that is responsible to eliminate systemic excess of BR was not 
targeted into this organelle. Interestingly enough, the mitochondrial membrane was 
intact, as indicated by no leakage of cytochrome C into cytosol.  The current findings 
also present primary evidence that microsomal CYP2A5 is used to constantly monitor 
excessive cellular BR levels and prevent its accumulation, whereas the mitochondrial 
CYP2A5 becomes significant under strong oxidative stress for local control of BR levels, 
when mitochondrial defence capacity against oxidative stress is upregulated by induction 
of HMOX1.   
                  
 
In summary, the present findings demonstrate:  
 
i) key enzymes regulating intracellular BR (HMOX1, BVR and CYP2A5) are 
targeted to mitochondria during oxidative stress; 
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ii) during oxidative stress, mitochondrial BR degradation is equally driven by 
ROS and CYP2A5, in contrast to microsomes, in which the degradation is 
driven mainly by CYP2A5;  
 
 
iii) mitochondrial CYP2A5-catalysed BR degradation is driven by the 
mitochondrial monooxygenase system;  
 
iv) during oxidative stress, mitochondrial BR degradation produce equal amounts 
of BV and dipyrroles, whilst in microsomes, the product is mainly BV. 
 
v) microsomal and mitochondrial CYP2A5 have equally strong affinity to BR; 
 
vi) targeting of key enzymes that regulate BR levels to mitochondria is not 
associated with initiation of apoptosis;  
 
 
Collectively, these results suggest that targeting of key BR regulatory enzymes 
to mitochondria confer their protection against oxidative stress.
 62 
 
                                                                                                   PYRAZOLE 
 
                      ER stress                                                                                                              Mitochondrial stress                
                                                              
                                                                                               COXIV               Ca
2+
accumulation                                                                
     HMOX1                    
                               BVR                                                                                             
            CYP2A5                   
UGT1A1                     ATP                                                                           
 
         
                                                                                                                        
                                                                                                                                                                                        cytochrome C release 
                                                                                                             
                                                      
                                                                                                                               
                                                            
                            
                                                                                                  
      
                  
                  
                                                                                                                                                                                          
Figure 5.12 Proposed protective mechanism through bilirubin regulation during oxidative stress induced by pyrazole intoxication. 
Increased microsomal and mitochondrial bilirubin metabolism enzymes activities (HMOX1, BVR and CYP2A5) levels ameliorate lipid 
peroxidation, preventing mitochondrial cytochrome C release. Reduced cellular ATP presumably increased glycolysis through PGC-1α - CYP2A5 
induction to restore ATP homeostasis (red arrows). These concerted activities are potentially in part to rescue cells from oxidative damage and 
apoptosis.
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6.  GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 GENERAL CONCLUSIONS 
 
 
The findings in this thesis contribute to the advancement of current knowledge 
in the research field of mitochondrial CYP enzymes as well as on the molecular events of 
hepatic cytoprotective mechanism in response to oxidative stress. Essentially, this study 
potentially describes a novel antioxidant mechanism that   implicates a CYP enzyme as 
part of the mitochondrial adaptive response to cellular stress. In this regard, it 
demonstrates:  
 
i) the involvement of CYP2A5 as a major catalyst for mitochondrial BR 
oxidation, to facilitate BR maintenance for cellular protection during 
ER stress;  
 
ii) that mitochondrial CYP2A5 and microsomal CYP2A5  are functional 
BR oxidases; and  
 
iii) non-enzymatic mitochondrial BR oxidation by ROS is dominant 
constitutively whilst the enzymatic, CYP2A5-catalysed become crucial 
during pyrazole-mediated ER stress.  
 
Given that mitochondrial oxidative damage is a crucial event in many 
pathologies, these molecular events may offer a potential therapeutic target for clinical 
intervention. 
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6.2 FUTURE DIRECTIONS 
 
 
The importance of mitochondrial oxidative damage in clinical conditions makes 
preventing it an attractive clinical approach that calls for fundamental and comprehensive 
knowledge on mitochondrial antioxidative regulation. This thesis has resolved but 
concurrently raised a few research questions that include: 
 
a) Is the temporal activation of the mitochondrial CYP2A5 and HMOX1 
enzymes coordinated or controlled in the same way as in microsomes? 
 
b) What are the sequential events leading to cellular apoptosis when 
mitochondrial BR homeostasis is lost?   
 
c) How is microsomal CYP2A5 directed to mitochondria during oxidative 
stress?  
 
d) How does coumarin and BR interact with mitochondrial CYP2A5 protein? 
 
e) Is the recruitment of BR regulating enzymes: the HMOX1, BVR and 
CYP2A5 a universal event in all organs or is it just liver specific? 
 
f) How much does BR contribute to overall mitochondria protection against 
oxidative stress? 
 
These questions, apart from narrowing the knowledge gap that will help to 
provide a complete map on adaptive response towards oxidative stress, is further 
significant given that oxidative stress has been implicated in pathological conditions  as 
diverse  as malignancies, cardiovascular diseases, neurodegenerative disorders and 
autoimmune diseases. It is therefore pertinent to understand fundamental cellular defence 
mechanisms particularly those at subcellular level notably mitochondria. This may in 
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turn help in developing more effective, novel clinical management and practices with 
improved targeting selectivity to impact the oxidative damages and disease outcomes. 
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8. APPENDICES 
Appendix 1 
 
List of Chemicals, Reagents and Instruments 
 
Chemical / Reagent Manufacturer / Supplier 
 
Pyrazole, coumarin, umbelliferone (7-
hydroxycoumarin),reduced 
nicotinamide adenine dinucleotide 
phosphate (β-NADPH), ascorbic acid, 
glycerol, glycine, mannitol, leupeptin, 
Hepes, phenylmethylsulfonyl-fluoride 
(PMSF), digitonin, bovine serum 
albumin (BSA), ethylenediamine 
tetraacetic acid (EDTA), DMSO, 
hemin, Glucose-6-phosphate 
(G6P),Glucose-phosphate 
dehydrogenase (G6PDH),Tween 20, 
sucrose 
 
Bilirubin and biliverdin  
 
Dithiothreitol (DTT)  
 
Goat anti-rabbit, goat anti-mouse, 
mouse anti-goat and rabbit anti-
chicken secondary antibodies 
conjugated with horseradish-
peroxidase 
 
 
Sigma-Aldrich, Sydney, Australia  
 
 
 
 
 
 
 
 
 
 
 
 
 
Frontier Scientific, Inc. ,Utah, 
USA 
Applichem, Germany 
 
Thermo Fisher Scientific Inc., 
Victoria, Australia  
 
 
 
 
 84 
 
Mouse monoclonal anti-HMOX1, 
rabbit polyclonal anti-BVR and anti-
cytochrome C antibodies 
 
Goat polyclonal anti-UGT1A1 
antibody 
 
Rabbit polyclonal anti-COX IV 
antibody  
 
Rabbit polyclonal anti-NPR antibody  
 
Chicken anti-CYP2A5 monoclonal 
antibody  
 
Anti-AdxR antibody 
 
 
Abcam, Australia 
 
 
 
Santa Cruz Biotechnology, INC 
 
 
Cell Signalling Technology, USA 
 
 
Assay Designs, New York, USA 
 
Kind gift from Dr Risto Juvonen, 
University of Kuopio, Finland  
 
 
Kind gift from Dr Alexey 
Kluchenovich, National Academic 
of Sciences, Republic of Belarus 
 
 
Instruments Manufacturer / Supplier 
 
Potter-Elvehjem Homogeniser  
 
HIMAC CP80 WX Preparative 
Ultracentrifuge 
 
Allegra X-15R Centrifuge 
 
 
Fluorescence Spectrometer LS55 
 
 
 
xMark
TM
 Microplate 
Spectrophotometer 
 
 
 
 
Sartorius, Goettingen, Germany 
 
Hitachi Koki Co. Ltd., Japan  
 
 
Beckman Coulter Inc, USA 
 
 
Perkin Elmer Ltd., Beaconsfield, 
Buckinghamshire, England 
 
 
Bio-Rad Laboratories Pty. 
Ltd.,Sydney Australia 
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Versadoc™ Molecular Imaging 
System  
 
 
 QTrap 5500 mass spectrometer 
equipped with an electrospray  (Turbo 
V) interface coupled to a HPLC 
system (Nexera)  
 
 
Cary Series UV-Vis 
Spectrophotometer 
 
 
Bio-Rad Laboratories Pty. Ltd., 
Sydney Australia 
 
 
AB Sciex, USA 
Shimadzu Corp., Kyoto, Japan 
 
 
 
 
Agilent Technologies, Australia 
 86 
 
Appendix 2 
 
Preparation of Liver Microsomal, Cytosolic and Mitoplasts Fractions 
 
Fresh livers pooled from 2 mice (about 3 g) were homogenised in isolation 
buffer (2 mM Hepes, 70 mM sucrose, 220 mM mannitol, 2 mM EDTA, 1 mM DTT, 0.5 
mM PMSF, 0.01 µg/µl leupeptin) using a motor-driven Potter-Elvehjem homogeniser 
(Sartorius, Goettingen, Germany). The homogenate was centrifuged at 2,000 x g for 10 
min. The supernatant was aspirated into a clean centrifuge tube and further centrifuged at 
14,000 x g for 15 min. The supernatant (post-mitochondrial fraction) was reserved to 
prepare microsomes. The mitochondrial pellet was washed by resuspending in isolation 
buffer and centrifuged again at 14,000 x g for 15 min. Resulting pellet was resuspended 
in isolation buffer, underlay with 27% sucrose using a 20-gauge blunt-end needle and 
centrifuged for 15 min at 14,000 x g. The pellet was washed and resuspended in buffer. 
An appropriate amount of 0.13 mg digitonin / mg protein was added to the mitochondrial 
suspension to remove outer mitochondrial membrane, thus producing mitoplasts. This 
mixture was incubated on ice with occasional agitation for 15 min. The reaction was 
stopped by resuspending the mixture with isolation buffer and centrifuged at 12,000 x g 
for 15 min. The resulting pellet was suspended in the buffer and centrifuged again for 15 
min at 12,000 x g. The mitoplasts was resuspended in dilution buffer (2 mM Tris-HCl, 
pH 7.4, 1 mM EDTA, 20% glycerol) and sonicated (4 x 30 seconds with 30 seconds 
intervening cooling times).  
 
Meanwhile, the post mitochondrial supernatant was centrifuged for 1 h at 
100,000 x g. The supernatant (cytosolic fraction) was removed and the pellet was 
resuspended in 3 ml to 5 ml of buffer and centrifuged again for 1 h at 100,000 x g. The 
microsomal pellet was collected and resuspended in dilution buffer. All the 
centrifugation procedures were done at 4
o
C. All samples were aliquoted and kept at -
80
o
C.  
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Appendix 3 
 
Coumarin Hydroxylase Activity 
 
Briefly, 300 μl of sample buffer [160 mM Potassium phosphate buffer (pH 7.4), 
8 mM MgCl2, 0.16 mM substrate coumarin] and 100 μl of microsomal / mitoplasts 
samples (containing 50 μg of protein) were placed in a glass tube. Reactions were started 
by the addition of 100 μl 7.5 mM NADPH and incubated with shaking for 20 min at 
37
oC. Reactions were stopped by the addition of 500 μl of 6.5% trichloroacetic acid 
(TCA) and centrifuged for 5 min at 2800 rpm. An aliquot of the supernatant (500 μl) was 
removed to a 2 ml quart cuvette and mixed thoroughly with 2 ml 1.6 M glycine / NaOH, 
pH 10.3. Hydroxycoumarin formation was then determined spectrofluorometrically at 
excitation wavelength of 390 nm and mission wavelength of 440 nm. A linear standard 
curve was achieved when the slit widths of the spectrofluorometer were set at 2.5 nm and 
5.0 nm for excitation and emission, respectively.  
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Appendix 4 
 
Western Immunoblotting 
 
Liver microsomal and mitoplasts proteins were separated by electrophoresis 
through a 4-12% Mini-Protean® TGX™ (Bio-Rad Laboratories Pty. Ltd., Sydney 
Australia), under denaturing condition and blotted overnight onto 0.2 µm PVDF 
membranes (Bio-Rad Laboratories Pty. Ltd., Sydney Australia). The blots were blocked 
in Tris-buffered saline (TBS) containing 0.1% Tween 20 and 5% non-fat milk for at least 
6 hours at room temperature. Immunoblot analysis was performed by incubating with 
anti-HMOX1 antibody, anti-CYP2A5 antibody, anti-UGT1A1 antibody, anti-NPR 
antibody, anti-COX IV, anti-BVR antibody and anti-cytochrome C antibody in dilutions 
of 1:250, 1:1000, 1:500, 1:5000, 1:1000, 1:5000, 1:200 respectively. All solutions 
contained 5% non-fat dairy milk. Blots were then incubated for 2 hours with horseradish-
peroxidase-conjugated secondary antibodies at room temperature. Detection was 
performed with commercial chemoluminescence reagents (Bio-Rad Laboratories Pty. 
Ltd., Sydney Australia). The intensity of each band was detected using Versadoc™ 
Molecular Imaging System. Finally, for the densitometric analysis, quantification was 
conducted using the software Image Lab™ 3.0 (Bio-Rad Laboratories Pty. Ltd., Sydney 
Australia).   
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Appendix 5 
 
HPLC/MS-MS conditions used to identify bilirubin and its oxidative metabolites 
 
 
 Transitions 
monitored (%) 
Declustering 
potential 
Collision 
Energy 
Retention 
time 
(mins) 
Bilirubin 585.5/299.2 (100) 
585.5/271.2 (10) 
75 
25 
60 
9.33 to 
10.37 
Biliverdin 583.5/297.2 (100) 
583.5/209.2 (20) 
110 
48 
83 
5.8 to 
6.16 
Metabolite 
m/z 301 
301.1/256.1 (100) 
301.1/242.1 (30) 
301.1/228.1 (25) 
75 
27 
27 
37 
2.54 to 
3.1 
Metabolite 
m/z 315 
315.1/287.1 (100) 
315.1/174.1 (60) 
75 
30 
32 
5.52 to 
5.8 
Metabolite 
m/z 333 
333.1/174.1 (100) 
333.1/231.1 (70) 
333.1/191.1 (70) 
75 
30 
25 
30 
3.34 to 
3.7 
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Appendix 6 
 
a) 
b)  
 
 
 
HPLC/MS-MS chromatograms of bilirubin, biliverdin and various dipyrroles.  a) bilirubin; 
ions m/z 585  and biliverdin; ions m/z 583  b) dipyrroles: ions m/z 301; ions m/z 333; ions m/z 
315 detected in order of their elution time. 
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Appendix 7 
 
 
Effect of ascorbic acid on Fenton oxidation of bilirubin (BR) 
 
 
Aim: To determine the concentration of ascorbic acid that   inhibits ROS in Fenton-
driven    bilirubin (BR) oxidation 
 
 
Experiment 
 
To test whether or not ascorbic acid can scavenge ROS that drive the chemical 
oxidation of BR, increasing concentrations of ascorbic acid (ranging from 2mM to 
200mM)  were added to the incubation mixtures  that comprise of 8 μmol H2O2, 0.26 
µmol FeCl3 and 10 µM BR.  BR oxidation rate was calculated by monitoring absorbance 
at wavelength 440nm for each minute for 20 minutes.  
 
 
Results and Discussion 
 
Fe-H2O2 (Fenton reagent) is an efficient oxidant for various organic substrates 
(Prousek, 2007). The oxidation of BR catalysed by H2O2 has been demonstrated 
previously (De Matteis et al., 1993; De Matteis et al., 2006). Ascorbic acid is a known 
scavenger of ROS (Tsai et al., 2007; Zhao et al., 1990). In the Fenton reaction of H2O2, 
0.26 µmol FeCL3 8 µmol H2O2 was used to produce ROS as below:  
  
Fe
2+
 + H2O2 → Fe
3+
 + ·OH + OH
- 
 
Fe
3+
 + H2O2 → Fe
2+
 + ·OOH + H
+ 
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These ROS, in particular ·OH and ·O2, are involved in the fractionation of BR to 
its smaller metabolites, dipyrroles (see Figure 1). At lower concentration, ascorbic acid 
did not seem to inhibit BR disappearance. However, addition of 200mM ascorbic acid 
effectively inhibited the rate of Fenton-driven BR disappearance to almost 100% (Figure 
2). This suggests that ascorbic acid is effective in scavenging ROS produced in the 
reaction. 200mM ascorbic acid will be used in subsequent experiments to determine the 
contribution of ROS to BR disappearance in mitochondria and microsomes.  
 
 
Conclusion 
 
It is concluded that 200mM ascorbic acid is an effective antioxidant to scavenge 
ROS in the Fenton-driven BR oxidation. This concentration is used to determine the 
contribution of ROS in microsomal and mitochondrial BR oxidations.
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Figure 1 Hypothetical mechanism for formation of BR oxidative metabolites (BOMs). Direct interaction of ROS with BR will produce BR 
peroxyradical and is suggested to be fragmented into ions m/z 301, 315 and 333. 
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Figure 2 Effect of ascorbic acid on bilirubin (BR) degradation rate in the chemical 
oxidation system. Activities were observed in the presence of different concentrations of 
ascorbic acid. The chemical oxidation is driven by ROS (mainly peroxyl radical) produced by 
Fenton reaction of H2O2. BR level was monitored by recording ΔA440 for 20 minutes. Results are 
given as means ± SD of three separate observations (n=3). *Significant different from control 
group, p < 0.05 (one-way ANOVA). 
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Abstract: The intracellular level of bilirubin (BR), an endogenous antioxidant that is cytotoxic at high 
concentrations, is tightly controlled within the optimal therapeutic range. We have recently described 
a concerted intracellular BR regulation by two microsomal enzymes: haem oxygenase 1 (HMOX1), 
essential for BR production and cytochrome P450 2A5 (CYP2A5), a BR oxidase. Herein, we describe 
targeting of these enzymes to hepatic mitochondria during oxidative stress. The kinetics of microsomal 
and mitochondrial BR oxidation were compared. Treatment of DBA/2J mice with 200 mg 
pyrazole/kg/day for 3 d increased hepatic intracellular protein carbonyls content and induced nucleo-
translocation of Nrf2. HMOX1 and CYP2A5 proteins and activities were elevated in microsomes and 
mitoplasts but not the UGT1A1, a catalyst of BR glucuronidation. A CYP2A5 antibody inhibited 75% of 
microsomal BR oxidation. The inhibition was absent in control mitoplasts but elevated to 50% after 
treatment. An adrenodoxin reductase antibody did not inhibit microsomal BR oxidation but inhibited 
50% of mitochondrial BR oxidation. Ascorbic acid inhibited 5% and 22% of the reaction in control and 
treated microsomes, respectively. In control mitoplasts the inhibition was 100%, which was reduced to 
50% after treatment. Bilirubin affinity to mitochondrial and microsomal CYP2A5 enzyme is equally 
high. Lastly, the treatment did not induce the release of cytochrome c into cytoplasm, indicating 
absence of mitochondrial membrane damage. Collectively, the observations suggest that BR regulatory 
enzymes are recruited to mitochondria during oxidative stress and BR oxidation by mitochondrial 
CYP2A5 is supported by mitochondrial mono-oxygenase system. The induced recruitment potentially 
confers membrane protection. 
 
 
 
 
Dear Dr. Burchiel,  
 
Ms No: TAAP-D-14-00773 
 
We submitted the above mentioned manuscript in July 2014, which was considered by one 
of your Associate Editors as an “innovation and priority publication” in TAAP provided that we 
include further evidence on relevant marker(s) that oxidative stress actually took place in 
pyrazole treated mice. 
 
Herein, we submit a revised manuscript that includes additional data on protein oxidation 
(indicated by elevated protein carbonyls content) and Nrf2 nuclear translocation as generally 
accepted markers of oxidative stress. In agreement with previous findings, the treatment regimen 
used in the present study evoked oxidative stress as demonstrated by; (i) elevated protein 
carbonyls content, particularly in the microsomes; and (ii) induced translocation of the key 
regulator of antioxidant response, Nrf2, from the cytoplasm to the nucleus. The Nrf2 nuclear 
translocation indicates initiation of a downstream protective mechanism, which is supported by a 
small but significant reduction of mitochondrial protein carbonyls content in the treated animals.  
 
We could show that under this condition the CYP2A5 (a bilirubin oxidase) and other key 
enzymes regulating the intracellular bilirubin levels are targeted into mitochondria. However, 
UGT1A1 — the sole microsomal enzyme that catalyses bilirubin glucuronidation for elimination 
from the body — is not targeted into mitochondria. Our observations support a hypothesis that 
the purpose for mitochondrial targeting of bilirubin regulatory enzymes during oxidative stress is 
to increase the local capacity to eliminate oxygen radicals and to protect mitochondria against 
excessive bilirubin concentration. This is supported by the observed lack of cytochrome c 
leakage into the cytosol, indicating absence of mitochondrial membrane damage. 
 
We believe that our findings contribute significantly to our understanding on the 
mechanism by which bilirubin levels in mitochondria are regulated and on its biological 
significance. 
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Abstract  32 
The intracellular level of bilirubin (BR), an endogenous antioxidant that is cytotoxic at high 33 
concentrations, is tightly controlled within the optimal therapeutic range. We have recently 34 
described a concerted intracellular BR regulation by two microsomal enzymes: haem 35 
oxygenase 1 (HMOX1), essential for BR production and cytochrome P450 2A5 (CYP2A5), a 36 
BR oxidase. Herein, we describe targeting of these enzymes to hepatic mitochondria during 37 
oxidative stress. The kinetics of microsomal and mitochondrial BR oxidation were compared. 38 
Treatment of DBA/2J mice with 200 mg pyrazole/kg/day for 3 d increased hepatic 39 
intracellular protein carbonyls content and induced nucleo-translocation of Nrf2. HMOX1 40 
and CYP2A5 proteins and activities were elevated in microsomes and mitoplasts but not the 41 
UGT1A1, a catalyst of BR glucuronidation. A CYP2A5 antibody inhibited 75% of 42 
microsomal BR oxidation. The inhibition was absent in control mitoplasts but elevated to 43 
50% after treatment. An adrenodoxin reductase antibody did not inhibit microsomal BR 44 
oxidation but inhibited 50% of mitochondrial BR oxidation. Ascorbic acid inhibited 5% and 45 
22% of the reaction in control and treated microsomes, respectively. In control mitoplasts the 46 
inhibition was 100%, which was reduced to 50% after treatment. Bilirubin affinity to 47 
mitochondrial and microsomal CYP2A5 enzyme is equally high. Lastly, the treatment did not 48 
induce the release of cytochrome c into cytoplasm, indicating absence of mitochondrial 49 
membrane damage. Collectively, the observations suggest that BR regulatory enzymes are 50 
recruited to mitochondria during oxidative stress and BR oxidation by mitochondrial 51 
CYP2A5 is supported by mitochondrial mono-oxygenase system. The induced recruitment 52 
potentially confers membrane protection.  53 
 54 
Keywords: Mitochondria, CYP2A5, HMOX1, Bilirubin, Oxidative stress, Endoplasmic 55 
reticulum 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
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Introduction 66 
In mitochondria, bilirubin (BR) is constitutively generated from haem in two successive 67 
reactions: haem oxygenase-catalysed degradation to biliverdin (BV), followed by biliverdin 68 
reductase-catalysed reduction to BR (Converso et al., 2006). At low constitutive level the 69 
free-radical quencher BR prevents accumulation of radical oxygen species (ROS) in 70 
mitochondria (Jansen et al., 2010), but at above 10 µM it disrupts mitochondrial membrane 71 
permeability, which in turn causes apoptosis (Rodrigues et al., 2002). Therefore, 72 
mitochondrial BR needs to be well regulated especially under oxidative stress conditions 73 
when BR production is markedly elevated following the induction of haem oxygenase -1 74 
(HMOX1). However, little is known about the regulatory mechanism of mitochondrial BR. 75 
The normal route of BR excretion in mammals is via the bile and involves the 76 
conversion of BR into its glucuronides, a reaction solely catalysed by the microsomal uridine-77 
diphosphate-glucuronosyltransferase 1A1 (UGT1A1) (Tukey & Strassburg, 2000). This 78 
enzyme however is not present in mitochondria (Radominska-Pandya et al., 2005). In 1969, 79 
Brodersen & Bartels described a BR oxidase in guinea-pig brain mitochondria. The reaction 80 
products include BV (Brodersen & Bartels, 1969). Subsequently, similar BR oxidase activity 81 
was described in rat liver mitochondria (Cardenas-Vazquez et al., 1986). Bilirubin oxidation 82 
was thus proposed as the main metabolic pathway for mitochondrial BR. However, the brain 83 
and liver enzymes were not identified.  84 
 Importantly, we have recently discovered that the liver microsomal cytochrome P450 85 
2A5 (CYP2A5) can function as an inducible BR oxidase that catalyses BR oxidation to BV 86 
(Abu-Bakar et al., 2011). In response to oxidative stress CYP2A5 induction paralleled but 87 
followed the induction of microsomal HMOX1 by several hours (Abu-Bakar et al., 2005). 88 
The CYP2A5 induction was delayed until cellular BR concentrations were elevated above the 89 
Km of 1-2 µM. At these concentrations BR was shown to stabilise the labile CYP2A5 protein 90 
by delaying its degradation (Abu-Bakar et al., 2011; Abu-Bakar et al., 2012). These 91 
observations would be consistent with BR inducing its own metabolism and CYP2A5 serving 92 
to clear BR generated by HMOX1 to ensure the levels of this essential but toxic compound 93 
do not exceed a safe threshold.  94 
 We have proposed that the significance of this regulatory mechanism is to ensure a 95 
rapid increase in intracellular antioxidant capacity during oxidative stress, by increasing the 96 
levels of BR, followed by an efficient elimination of any excess of BR as soon as cellular 97 
ROS reached physiological level (Abu-Bakar et al., 2013). The kinetics of CYP2A5 98 
4 
 
catalysing BR oxidation seem ideal for this purpose as the Km for BR is roughly one tenth of 99 
the cytotoxic concentrations (Abu-Bakar et al., 2005; Abu-Bakar et al., 2012).  100 
Earlier observations that a fraction of microsomal HMOX1 is targeted to mitochondria 101 
in response to oxidative stress (Converso et al., 2006; Srivastava and Pandey, 1996) indicate 102 
an increased mitochondrial BR production. The fact that the CYP2A5 is also targeted to 103 
mitochondria in response to oxidative stress (Genter et al., 2006; Honkakoski et al., 1988) 104 
raises an interesting question if mitochondria are equipped with a similar system to that of 105 
microsomes in regulating local BR homeostasis. 106 
 In addressing this question, we explored the induction profile of key BR regulatory 107 
enzymes in the microsomes and mitochondria of the mouse liver in response to oxidative stress. 108 
We also investigated the contribution of mitochondrial CYP2A5 to BR oxidation. We observed 109 
that oxidative stress — indicated by elevated intracellular protein carbonylation and nucelo-Nrf2 110 
levels — markedly increased HMOX1 and CYP2A5 proteins and activities in the microsomes 111 
and mitochondria. The induction of CYP2A5 in mitochondria was stronger than in the 112 
microsomes. We also observed that mitochondrial CYP2A5 oxidised BR with an affinity similar 113 
to that of the microsomal enzyme but required the mitochondrial electron transfer chain for its 114 
activity. During oxidative stress the mitochondrial CYP2A5-catalysed BR oxidation was highly 115 
significant, whilst under normal condition oxidation by ROS was the dominant pathway. By 116 
contrast, the microsomal BR oxidation was mainly driven by the CYP2A5 both under normal 117 
and oxidative stress conditions. Additionally, protein carbonyls content in microsomes was 118 
increased by 200% but in mitochondria it was reduced by about 25% of control. This suggests 119 
marked oxidative damage to microsomal proteins, whilst the mitochondrial proteins seemed to 120 
be well protected, which is further supported by observed lack of mitochondrial cytochrome c 121 
leakage into the cytosol in treated mice. Collectively, our observations indicate that induced 122 
recruitment of key bilirubin regulatory enzymes to mitochondria potentially confers 123 
mitochondrial protection against severe oxidative damage.  124 
 125 
Materials and Methods 126 
Chemicals and antibodies. Coumarin, mesoporphyrin, umbelliferone (7-hydroxycoumarin), 127 
pyrazole, β-NADPH, glycerol, mannitol, leupeptin, Hepes, phenylmethylsulfonyl-fluoride 128 
(PMSF), digitonin, Percoll, bovine serum albumin (BSA), ethylene glycol tetraacetic acid 129 
(EGTA), ethylenediamine tetraacetic acid (EDTA), dimethyl sulfoxide (DMSO) and Tween 130 
20 were purchased from Sigma-Aldrich (Sydney, Australia). Bilirubin, mesobilirubin, 131 
biliverdin and sucrose were from Frontier Scientific, Inc. (Utah, USA) and Ajax Chemical 132 
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(Sydney, Australia), respectively. Dithiothreitol (DTT) was purchased from Applichem 133 
(Germany). Goat anti-rabbit, goat anti-mouse, mouse anti-goat and rabbit anti-chicken 134 
antibodies conjugated with horseradish-peroxidase were from Thermo Fisher Scientific Inc. 135 
(Victoria, Australia). Rabbit polyclonal anti-COX IV antibody was from Cell Signalling 136 
Technology (NY, USA) whereas anti-cytochrome P450 reductase antibody was from Assay 137 
Designs (NY, USA). Rabbit polyclonal anti-Nrf2 (ab92946), anti-biliverdin reductase 138 
(ab19260), anti-β-actin (ab8227), and mouse monoclonal anti-HMOX1 (ab13248) antibodies 139 
were sourced from Abcam (Cambridge, UK). Rabbit polyclonal anti-Lamin B1 (sc20682) 140 
and goat polyclonal anti-UGT1A1 (sc27419) antibodies were purchased from Santa Cruz 141 
Biotechnology Inc. (Texas, USA). Rabbit polyclonal anti-CYP2A5 antibody and anti-142 
adrenodoxin reductase antibody was sourced from Dr Risto Juvonen, University of Kuopio, 143 
Finland and Dr Sergej Usanov, National Academic of Sciences, Republic of Belarus, 144 
respectively. The specificity of these antibodies in inhibiting CYP2A5 activity (coumarin 7-145 
hydroxylase) and adrenodoxin reductase activity, respectively, have been well documented in 146 
various models (Abu-Bakar et al., 2005; Asikainen et al., 2003; Chernogolov et al., 1997; 147 
Guzov et al., 1993;  Honkakoski et al., 1988; Honkakoski et al., 1989; Honkakoski et al., 148 
1993; Juvonen et al., 1988; Kaipainen et al., 1984; Usanov et al., 1984; Usanov et al., 1989; 149 
Usanov et al., 1990). 150 
 151 
Treatment of animals. All experimental procedures involving handling of laboratory animals 152 
were conducted in accordance with the Australian National Health and Medical Research 153 
Council (NHMRC) Code of Practice for care and use of experimental animals, and approved 154 
by the Queensland Forensic and Scientific Services Animal Ethics Committee (FSS-AEC 155 
Approval No. 10P01). Male DBA/2J mice were purchased from the Animal Resource Centre, 156 
Western Australia. They were group-housed, maintained at a 12 hour light/dark cycle, and 157 
had access to standard rodent chow ad libitum. The mice were randomly allocated into 158 
treated and control groups (6 mice per group). Induction of oxidative stress was achieved by 159 
intraperitoneal administration of 200 mg pyrazole/kg bwt/day for three days (Bae et al., 2012; 160 
Gilmore and Kirby, 2004). The animals in control group were given normal saline only. 161 
Twenty-four hours after the final dose the animals were euthanised with CO2/O2 overdose 162 
and their livers excised. 163 
 164 
Preparations of subcellular fractions. Microsomes and mitochondria were prepared from 165 
fresh liver at 0-4
o
C as described by Genter et al. (2006) with some modifications. Briefly, 166 
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fresh livers were homogenised in isolation buffer (2mM Hepes, 70mM sucrose, 220mM 167 
mannitol, 2mM EDTA, 1mM DTT, 0.5mM PMSF, 0.01 µg/µl leupeptin) using a motor-168 
driven Potter-Elvehjem homogenizer (Sartorius, Goettingen, Germany). The homogenate was 169 
centrifuged (2,000 x g) for 10 minutes at 4
o
C. The supernatant was aspirated into a clean tube 170 
and further centrifuged (14,000 x g) for 15 minutes at 4
o
C. The supernatant (post-171 
mitochondrial fraction) was used to prepare microsomes. The mitochondrial pellet was 172 
washed by resuspending in isolation buffer and centrifuged again at 14,000 x g for 15 173 
minutes (4
o
C). Resulting pellet was resuspended in isolation buffer, underlay with 27% 174 
sucrose using a 20-gauge blunt-end needle and centrifuged for 15 minutes at 14,000 x g 175 
(4
o
C). The pellet was washed and resuspended in isolation buffer. To increase the purity of 176 
mitochondrial fractions the pellet was treated with an appropriate volume of 0.13 mg 177 
digitonin/mg protein to strip off the outer membrane that is associated with microsomes. This 178 
mixture was incubated on ice with occasional agitation for 15 minutes at 4
o
C. The reaction 179 
was stopped by resuspending the mixture with isolation buffer and centrifuged (12,000 x g) 180 
for 15 minutes at 4
o
C. The resulting pellet was suspended in the buffer and centrifuged again 181 
for 15 minutes at 12,000 x g. The mitoplasts were resuspended in dilution buffer (2mM Tris-182 
HCl, pH 7.4, 1mM EDTA, 20% glycerol), aliquoted and stored at -80
o
C until required. 183 
 Enzyme activity assays and Western Immunoblot were performed with mitoplasts as 184 
the enzymes studied (HMOX1, CYP2A5, UGT1A1), and cytochrome c are integrated in the 185 
inner mitochondrial membrane (Cortese et al., 1998; Gallet et al., 1997; Genter et al., 2006; 186 
Honkakoski et al., 1988; Rytomaa et al., 1995), which is intact in the mitoplasts. Prior to 187 
enzyme activity assays the purified mitoplasts were brought down by centrifugation, 188 
suspended in dilution buffer and sonicated (4 X 30 s with 30 s intervening cooling time) to 189 
disrupt the inner membrane to allow NADPH and substrates to reach the enzymes of interest. 190 
 Nuclei fractions were prepared in the cold (2-4
o
C) as previously described (Wang, 191 
1967) with modifications. Briefly, fresh livers were rinsed in ice-cold PBS. The livers were 192 
cut into small pieces in 6 ml of homogenisation buffer (HB) [containing final concentrations 193 
of 10 mM Hepes pH 7.6, 15 mM KCl, 1mM EDTA, 1M sucrose, 10% glycerol, 0.5 mM 194 
spermidine, 0.15 mM spermine, 0.5 mM DTT, 0.5 mM PMSF, and 10 μg/ml leupeptin] and 195 
homogenized  in Potter-Elvehjem homogenizer (Sartorius, Goettingen, Germany). The liver 196 
homogenate then was gently poured into a centrifuge tube containing 5 ml of the HB and 197 
centrifuged at 50,000 x g, 4
o
C for 50 min.  The white pellet obtained was dissolved in 1 ml of 198 
TGEM [containing final concentrations of 50 mM Tris pH 8.0, 40% glycerol, 5 mM EDTA, 199 
and 5 mM MgCl2] and centrifuged at 600 x g, 4
o
C for 5 min. The pellet (nuclei) was 200 
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resuspended in 0.7 ml TGEM, aliquoted and stored in –80oC. When needed nuclear proteins 201 
were extracted by dialysis. The purified nuclei was brought down by centrifugation (600 x g, 202 
4
o
C for 5 min) and resuspended in 2 volumes of suspension buffer [20 mM Hepes pH 7.6, 203 
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol, 0.5 mM DTT, and 0.5 mM 204 
PMSF]. The nuclei suspension was stirred with a magnetic flea for 30 min at 4
o
C and 205 
centrifuged at 1200 x g, 4
o
C for 5 min. The supernatant was dialyzed overnight  on a 0.025 206 
μm nitrocellulose membrane (Millipore, Massachusetts, USA) against 100 volumes of 207 
dialysis buffer [20 mM Hepes pH 7.6, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5 mM 208 
DTT, and 0.5 mM PMSF] at 4
o
C. The dialyzed supernatant was centrifuged at 1200 x g, 4
o
C 209 
for 5 min to bring down impurities. The supernatant, which contained nuclear proteins were 210 
aliquoted and stored at –80oC. 211 
 212 
Protein analysis. Protein concentrations of the subcellular fractions were determined by the 213 
Lowry method (Lowry et al., 1951). Protein concentrations of the cytosol, microsomes, 214 
mitoplasts, and nuclei ranged from 7.8±1 µg/µl (0.78±0.09 mg/g wet liver weight) to 215 
16.3±1.04 µg/µl (3.4±0.3 mg/g wet liver weight). Protein fractions were separated by 216 
electrophoresis through a 4-12% Mini-Protean® TGX™ (Biorad Laboratories, USA), under 217 
denaturing condition and blotted overnight onto 0.2 µm PVDF membranes (Biorad 218 
Laboratories, USA). The blots were blocked overnight in Tris-buffered saline (TBS) 219 
containing 0.1% Tween 20 and 5% non-fat milk at 4
o
C. To assess the purity of mitochondrial 220 
fraction, the blots were then incubated with the following antibodies overnight at 4
o
C: anti-221 
COX IV antibody and anti-P450 reductase antibody (1:1000 dilutions). To determine the 222 
levels of key BR regulatory proteins the blots were incubated with HMOX1, biliverdin 223 
reductase (BVR), UGT1A1, CYP2A5, or antibodies for 3 hours at room temperature (1:500 224 
to 1:2000 dilutions). Detection of a key regulator of antioxidant response — the nuclear 225 
factor (erythroid-derived 2)-like 2 (Nrf2) — as indicator of oxidative stress was by incubating 226 
the blots with anti-Nrf2 antibody. The blots were then incubated for 1 hour with horseradish-227 
peroxidase-conjugated secondary antibodies (1:5000 dilutions). After further washing with 228 
TBS containing 0.05% Tween 20 and 5% non-fat milk, blots were incubated in 229 
chemiluminescence reagents (Biorad Laboratories, USA). Finally, bands’ intensities were 230 
detected using Versadoc™ Molecular Imaging System (Biorad Laboratories, USA). The 231 
results were expressed as relative density where the signals of a specific antibodies were 232 
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normalised against the loading control signals: β-Actin for cytosolic and microsomal 233 
fractions, and COXIV for mitochondrial fractions. 234 
 235 
Protein carbonyls assay. Protein carbonyl groups that are formed when proteins are 236 
oxidatively damaged have been increasingly used as biomarkers for oxidative stress (Dalle-237 
Donne et al., 2003). The carbonyls were quantitated spectrometrically using 2,4-238 
dinitrophenylhydrazine (DNPH) as previously described (Reznick & Packer, 1994; Fagan et 239 
al., 1999) with modifications. Cytosolic, microsomal and mitochondrial proteins (1- 3 240 
mg/assay) were precipitated with 10 volumes of HCl-acetone (3:100) (v/v). The proteins 241 
were centrifuged down at 6000 x g for 10 min. The pellets were washed with 2 x 2 ml of 242 
HCl-acetone to remove chromophores, which may interfere with the assay. The protein 243 
pellets were then washed twice with 2 ml of 10% TCA. After the final wash, protein pellets 244 
were resuspended in 500 μl of 2 M HCl to which 500 μl of 10 mM DNPH (in 2 M HCl) was 245 
added and vortexed every 5 min for 20 min at room temperature. Protein blanks were 246 
prepared by adding 500 μl of 2 M HCl instead of DNPH to the assay tubes containing protein 247 
sample. After mixing, 500 μl of 30% TCA was added to each tube, the samples vortexed then 248 
placed on ice for 10 min. Following centrifugation (3 min at 11,000 x g), the supernatant was 249 
discarded and the pellets were subjected to extensive washing with 2 x 2 ml of 20% TCA 250 
followed by 3 x  2 ml of ethanol-ethylacetate (1:1) (v/v) washes to remove any unreacted 251 
DNPH. The final precipitates were dissolves in 1 ml of 6 M guanidine hydrochloride in 20 252 
mM potassium dihydrogen phosphate (pH 2.3) and left for 30 min at 37
o
C with vortex 253 
mixing. Any insoluble materials were removed by additional centrifugation (6000 x g for 10 254 
min). The protein carbonyl content was calculated from the absorbance measurement at 380 255 
nm and extinction coefficient ε = 22,000 M-1cm-1 (Johnson, 1953). Protein samples with 256 
A280/A260 nm ratio of less than 1 were incubated with streptomycin sulphate (final 257 
concentration of 1%) for 15 min at room temperature to remove nucleic acids that may 258 
erroneously contribute to higher estimation of carbonyls. 259 
 260 
Enzyme activity measurement. Coumarin 7-hydroxylase (COH) — indicator of CYP2A5 261 
activity — was determined spectrofluorometrically by assessing 7-hydroxylase activity 262 
towards the substrate coumarin (100 µM final concentration) using 0.1 mg of mitoplast or 263 
microsomal proteins incubated for 20 minutes as previously described (Abu-Bakar et al., 264 
2004).  265 
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Haem oxygenase activity was measured by detecting BR generation as previously 266 
described (Ryter et al., 2000). Briefly, microsomes or mitoplasts were added to a reaction 267 
mixture and mouse liver cytosol was used as a source of biliverdin reductase. The reaction 268 
was done in the dark. BR concentration was calculated as the difference in absorbance 269 
between 464 and 530 nm, using an extinction coefficient of 40 mM
-1
cm
-1
. 270 
NADPH P450 reductase and cytochrome c oxidase activities were determined with the 271 
respective assay kits (Cat Nos: CY0100 and CYTOCOX 1, Sigma Aldrich, Sydney, 272 
Australia) in accordance with the manufacturer’s instruction. 273 
Biliverdin reductase (BVR) activity was measured according to published method 274 
(Tenhunen et al., 1970) with modifications. In brief, the activity was assayed in buffer 275 
containing 100 mM KPO4 pH 7.4, 25 μM biliverdin and 0.2 mg/ml protein. The mixture was 276 
incubated for 5 minutes at 37
o
C and the reaction was initiated with the addition of 100 µM 277 
NADPH. Bilirubin formation was determined spectrophotometrically at 450 nm, using the 278 
extinction coefficient 56 mM
-1
cm
-1
. 279 
 280 
Bilirubin oxidation analysis. Bilirubin oxidation was assessed by determining the rate of 281 
bilirubin disappearance spectrometrically as previously described (Abu-Bakar et al., 2005; 282 
Arthur et al., 2012). In the study of the inhibitory effects of anti-CYP2A5 antibody, the final 283 
concentration of microsomal or mitoplast protein used was 5 µg/ml. Increasing 284 
concentrations of the antibody were then added to obtain concentration ratios to 285 
microsomal/mitoplast protein ranging from approximately 0.0005 to 2.0. Twenty µM BR (in 286 
DMSO) was added and the reaction was initiated by addition of NADPH and incubated at 287 
37
o
C for 20 minutes. The same condition was employed when the inhibitory effects of 200 288 
mM ascorbic acid and anti-adrenodoxin reductase (AdxR) antibody on the bilirubin-289 
degrading activity of the induced microsomes and mitoplast were studied. 290 
Screening of putative dipyrroles was performed as previously described (Abu-Bakar et 291 
al., 2011; Arthur et al., 2012). Briefly, the reaction mixtures were incubated for 1 hour after 292 
which samples were filtered using 0.45µm filter membrane (Milipore) and immediately 293 
injected to a HPLC-MS/MS (AB/Sciex AP14000Q mass spectrometer, USA) equipped with 294 
an electrospray  (TurboV) interface coupled to a HPLC system (Prominence Model XYZ, 295 
Shimadzu Corp., Kyoto, Japan). Separation was achieved using a 2.5µm 50 x 2mm Synergi 296 
MAX RP column (Phenomenex, Torrance, CA, USA) run at 40
o
C, and mobile phase flow 297 
rate of 0.5ml/min with a linear gradient starting at 5% B for 1.0 min, ramped to 80% B in 10 298 
min, held for 1 min, to 5% in 0.2 min and equilibrated for 3 min (mobile phase A=1% 299 
 10 
 
acetonitrile/HPLC grade water, mobile phase B= 95% acetonitrile/HPLC grade water, both 300 
containing 5mM ammonium acetate). The mass spectrometer was operated in the positive 301 
ion, multiple reactions monitoring mode using nitrogen as the collision gas under the 302 
following conditions: declustering potential was 75 or 110 (biliverdin only), and the collision 303 
energy was between 25 and 83eV.  304 
 305 
Kinetics and statistical analysis. Enzyme kinetic parameters were determined by GraphPad 306 
Prism 5 kinetics programme from GraphPad Software Inc (La Jolla, CA, USA). It uses a non-307 
linear regression method of curve fitting and the Runs test of residuals to determine 308 
statistically whether experimental data are randomly distributed around the curve with 95% 309 
confidence. The Ki value was determined by plotting observed Km (Y-axis) vs bilirubin 310 
concentrations (X-axis). For data other than enzyme kinetic parameters Student’s t-test was 311 
used for comparisons between two groups. Mean differences were considered significant 312 
when p < 0.05. 313 
 314 
Results 315 
Assessment of purity of microsomal and mitochondrial fractions. 316 
 The purity of the microsomal and mitoplast fractions was assessed by measuring the 317 
presence of cytochrome C oxidase IV (COX IV) and NADPH P450 reductase (NPR), 318 
markers of mitochondrial inner membrane and endoplasmic reticulum, respectively. Western 319 
immunoblotting showed that a minimal amount of NPR was present in the mitoplast (Fig. 320 
1A), which commensurate with the NPR activity (approximately 10% of the activity in 321 
microsomes) (Fig.1B). This suggests that most but not all of the endoplasmic reticulum (ER) 322 
associated with mitochondria has been removed. On the other hand, no COX IV-reactive 323 
band was found in the microsomal fraction (Fig. 1A) although a minimal microsomal COX 324 
activity (2-4% of mitoplast activity) was present (Fig 1B). This indicates a high microsomal 325 
enrichment with only minor mitochondrial contamination. Subsequent data analysis was 326 
offset against the 10% microsomal contamination and 2-4% mitoplasts contamination.  327 
 328 
Pyrazole induces oxidative stress in the liver 329 
 Pyrazole (PYR) doses used in this study were previously shown to cause oxidative 330 
stress in the mouse liver (Gilmore and Kirby, 2004; Lu et al., 2008). Particularly, PYR was 331 
shown to induce endoplasmic reticulum stress and elevate protein carbonyls content in a 332 
time- and dose-dependent manner (Gilmore and Kirby, 2004). The treatment indeed evoked 333 
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endoplasmic reticulum stress as indicated by a significant increase (200%) of protein 334 
carbonylation in the microsomes (Fig. 2A). It is noted that the carbonyls content in control 335 
mitoplasts was significantly higher (by about 40 - 50%) than in control cytosol and 336 
microsomes (Fig. 2A). This is perhaps to be expected as mitochondria produce oxygen 337 
radicals  during cellular respiratory, moreso than the other organelles. Interestingly, PYR 338 
reduced mitochondrial protein carbonyls content by 25% (Fig. 2A), indicating mitochondrial 339 
proteins were protected against oxidative damage when microsomal proteins were 340 
signficantly oxidised. This observation is paralleled with the PYR-induced accumulation of 341 
Nrf2 — a key regulator of antioxidant response — in the nucleus (Fig. 2B & C). Previous 342 
findings have also observed elevated Nrf2 levels in livers of mice treated with PYR 343 
(Cederbaum, 2013; Lu et al., 2008).  344 
 345 
Pyrazole accumulates BR regulatory enzymes in microsomes and mitoplasts  346 
 Importantly, during oxidative stress HMOX1 and CYP2A5 immunoreactive bands were 347 
substantially increased in microsomes and mitoplasts (Fig. 3). Compared to controls HMOX1 348 
induction in the microsomes was stronger than that of CYP2A5 (2-fold more than the 349 
CYP2A5 induction) (Fig. 3B). By contrast, HMOX1 induction in the mitoplasts was 2-fold 350 
less than the CYP2A5 induction (Fig. 3B).  351 
 Although HMOX1 protein induction in mitoplasts was two times less than in 352 
microsomes (Fig. 3B), elevation of its catalytic activity was similar in both organelles 353 
(increased by 4-fold compared to control) (Table 1). This suggests differences in the 354 
reactivity of anti-HMOX1 antibody vis-à-vis the mitochondrial and microsomal HMOX1. 355 
This is plausible as some microsomal proteins are targeted to mitochondria as truncated 356 
proteins (Addya et al., 1997; Anandatheerthavarada et al., 1999; Anandatheerthavarada et al., 357 
2009). In the case of HMOX1, the precise mitochondria targeting signal has not been 358 
identified. However, recent study demonstrated that deletion of N-terminal of the microsomal 359 
HMOX1 protein resulted in markedly increased mitochondrial targeting (Bansal et al., 2014). 360 
On the other hand, the strong induction of microsomal and mitochondrial CYP2A5 protein 361 
was reflected in 10-fold increase and 60-fold increase of the CYP2A5 catalysed coumarin 7-362 
hydroxylase (COH) activity, respectively (Table 1).   363 
It is noted that UGT1A1, the sole enzyme that catalyses BR glucuronidation, was not 364 
detected in mitoplasts (Fig. 3), confirming previous observation that UGT enzymes are not 365 
known to be present in the mitochondria (Radominska-Pandya et al., 2005). PYR, however 366 
reduced microsomal UGT1A1 by 40% (Fig. 3B), indicating that elimination of BR by 367 
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glucuronidation was significantly hampered during oxidative stress. Additionally, PYR did 368 
not affect the activity and protein levels of cytosolic BVR (Fig. 3 and Table 1), the enzyme 369 
that reduces BV to BR. By contrast, BVR protein and activity increased by 100% in treated 370 
mitoplasts (Fig. 3 and Table 1).  371 
Taken together, these observations indicate that in response to PYR-induced oxidative 372 
stress BR producing, oxidising and reducing enzymes are recruited to mitochondria. The 373 
absence of UGT1A1 in mitochondria further suggests that instead of being eliminated 374 
through glucuronidation, local BR is metabolised by other pathway, perhaps through 375 
oxidation by the CYP2A5. 376 
 377 
Pyrazole treatment increases BR degradation in microsomes and mitoplasts 378 
We have previously shown that CYP2A5-dependent BR oxidation exists in microsomes 379 
and the activity is substantially increased in response to cadmium-induced oxidative stress 380 
(Abu-Bakar et al., 2005). In exploring the existence of this system in mitochondria and its 381 
inducibility in response to oxidative stress we measured BR degradation rate 382 
spectrometrically in incubations with mitoplasts and microsomes. Fig. 4A shows that BR 383 
disappears in the presence of control microsomes and mitoplasts, and that the disappearance 384 
rate increased in PYR-treated microsomes and mitoplasts. Interestingly, the rate in control 385 
microsomes and mitoplasts is similar but in treated microsomes it increased 3 times more 386 
than in treated mitoplasts (200% increase in treated microsomes; 68% increase in mitoplasts) 387 
(Fig. 4A). The observations suggest that while a BR oxidation system exists in both 388 
organelles it differs in the kinetics of inducibility. 389 
 390 
Role of CYP2A5 in BR oxidation in microsomes and mitoplasts. 391 
 It has been hypothesised that the initial step in BR oxidation is hydrogen abstraction 392 
from the central methylene bridge of the tetrapyrrole, followed by loss of another hydrogen to 393 
give BV (De Matteis et al., 2006). This has been shown to take place in the active site of 394 
CYP2A6 enzyme (the human orthologue of CYP2A5) (Abu-Bakar et al., 2012). In a system 395 
where ROS is accessible, random oxygen binding takes place subsequent to hydrogen 396 
abstraction to form BR peroxyradical, which is then fragmented into putative dipyrroles with 397 
m/z values of 301, 315, and 333 (Abu-Bakar et al., 2011; De Matteis et al., 2006). The BR 398 
peroxyradical can also be formed by a superoxide anion attacking BR directly, followed by 399 
fragmentations into the putative dipyrroles (Abu-Bakar et al., 2011; Abu-Bakar et al., 2012). 400 
Accordingly, BV is the predominant product of the CYP2A5-catalysed BR oxidation, whilst 401 
 13 
 
dipyrroles are major products of ROS-driven BR oxidation (non-enzymatic oxidation) (Abu-402 
Bakar et al., 2011; Abu-Bakar et al., 2012). 403 
Given that both microsomes and mitochondria produce ROS through leakage of their 404 
respective electron transfer systems (Cadenas and Davies, 2000; Zangar, 2004), the observed 405 
BR disappearance activity — depicted in Fig. 4A — may be caused by both enzymatic and 406 
non-enzymatic oxidations. To assess the contribution of the respective oxidation pathways in 407 
the observed BR disappearance we added vitamin C — a ROS scavenger — to the incubation 408 
mixtures to exclude random oxidation by ROS.   409 
Vitamin C did not significantly inhibit BR degradation in control microsomes but 410 
inhibited about 20% of the reaction in treated microsomes (Fig. 4B), indicating that random 411 
oxidation by ROS is a minor event in microsomes. By contrast, ROS driven BR 412 
disappearance seems to be the major, if not the only degradation pathway in the control 413 
mitoplasts, as 100% of the BR disappearance was blocked by vitamin C (Fig. 4B). In the 414 
treated mitoplasts, however, vitamin C blocked only 54% of BR degradation (Fig. 4B), 415 
suggesting that in response to oxidative stress ROS-independent oxidation is as important as 416 
the ROS-dependent oxidation. 417 
To explore the contribution of CYP2A5 to BR oxidation in both organelles we first 418 
screened BV and dipyrroles formations in incubations with either microsomes or mitoplasts. 419 
In the second set of experiments we used anti-CYP2A5 antibody to inhibit CYP2A5-420 
catalysed BR oxidation.  421 
The absence of BV formation in the chemical oxidation of BR by Fe-EDTA/ H2O2 422 
system (Fig. 5A) confirms published observations that dipyrroles are the major products of 423 
non-enzymatic BR oxidation (Abu-Bakar et al., 2011; Abu-Bakar et al., 2012; De Matteis et 424 
al., 2006). The formation of BV and dipyrroles in incubations with microsomes or mitoplasts 425 
(Fig. 5B) suggests BR oxidation in these organelles is driven by enzymatic and non-426 
enzymatic pathways. In control microsomes BV formation predominates that of the 427 
dipyrroles (Fig. 5B). PYR treatment increased the formation of dipyrroles (Fig. 5B), 428 
suggesting elevation in ROS-driven BR oxidation, which commensurate with ascorbic acid 429 
inhibition depicted in Fig. 4B. In the case of mitoplasts, dipyrroles formation predominates 430 
that of BV. The fold-increased of BV formation is 4 times that of dipyrroles in treated 431 
mitoplasts (Fig. 5B). This observation suggests that in mitoplast the enzymatic oxidation is as 432 
important as the ROS-mediated oxidation, which parallels with our earlier observation in 433 
ascorbic acid inhibition study (Fig. 4B).  434 
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Fig. 6 shows that anti-CYP2A5 antibody blocks BR degradation in both organelles. It 435 
inhibited microsomal BR oxidation by 70 - 72% (Fig. 6A). The amount of CYP2A5 antibody 436 
needed to achieve the inhibition in treated microsomes was about 13-fold higher than in the 437 
control microsomes, indicating that larger amounts of CYP2A5 protein responsible for BR 438 
disappearance were present in the treated samples. This commensurate with the observed 439 
protein levels and COH activity (Fig. 3 and Table 1). By contrast, we did not observe 440 
significant inhibition in control mitoplasts. However, a maximum of 50% inhibition was 441 
observed after PYR treatment (Fig. 6B), which parallels with the increased CYP2A5 activity 442 
(Table 1). These results suggest that the other mechanism for BR degradation — in addition 443 
to oxidation by ROS — is via CYP2A5-catalysed oxidation, as together these two metabolic 444 
pathways would explain 100% of the BR degradation in each case. 445 
To confirm that the enzymatic BR oxidation is supported by the respective mono-446 
oxygenase complexes in each organelle, anti-adrenodoxin reductase (AdxR) antibody was 447 
added to the incubations with treated microsomes or treated mitoplasts.  AdxR, is a key 448 
component of the mitochondrial electron transfer chain (ETC) that provides electrons to the 449 
mitochondrial CYP catalysed reactions and is absent in the microsomes. Fig.  6C shows that 450 
the antibody did not inhibit microsomal BR disappearance, indicating that the microsomal 451 
BR degradation is essentially driven by the microsomal ETC. This observation also 452 
confirmed that the microsomal fractions are essentially free from mitoplast contamination. By 453 
contrast, the anti-AdxR antibody inhibited 50% of BR degradation in mitoplasts (Fig. 6C), 454 
which is in agreement with Fig. 4B & 5B and confirms that in treated mitoplasts 50% of the 455 
oxidation is driven by mitochondrial CYP2A5.      456 
 457 
Microsomal and mitochondrial CYP2A5 enzymes have similar affinity to BR. 458 
We have previously established that both the microsomal and mitochondrial CYP2A5 459 
enzymes have a high affinity towards coumarin, which can be used as a diagnostic substrate 460 
for the enzyme in both organelles (Honkakoski et al., 1988). We also showed in this study 461 
(Fig. 6C) and in earlier investigations that the enzyme has been modified to fit in the electron 462 
transfer chains of the respective organelles (Honkakoski et al., 1988). To further characterise 463 
the interaction of BR with mitochondrial CYP2A5 we inhibited the coumarin 7-464 
hydroxylation (COH) activity in treated mitoplasts with different concentrations of BR.  465 
Fig. 7A shows that inhibition of mitochondrial coumarin 7-hydroxylation by BR is of a 466 
mixed type that affected both the Vmax and Km, where the Vmax is reduced and the Km is 467 
increased (Fig. 7B). The Km for coumarin 7-hydroxylation is 6.14±0.5 (Fig. 7C), which is 13 468 
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times more than the Km for microsomal coumarin 7-hydroxylation (Abu-Bakar et al., 2005), 469 
suggesting that coumarin affinity to the mitochondrial CYP2A5 is less than the affinity to 470 
microsomal CYP2A5. This aligns with previous observations that targeted xenobiotic-471 
metabolizing CYPs are modified to depend on mitochondrial ETC for a supply of electrons 472 
for catalytic activity toward altered substrate specificity/affinity (reviewed in Kinonen et al., 473 
1995).  474 
 The plot Km observed vs BR concentrations (Fig. 7C) yielded a linear graph, which 475 
confirmed the competitiveness of BR inhibition to the reaction with Ki = 2.67 μM. This 476 
indicates that BR affinity for mitochondrial CYP2A5 is as high as the reported affinity for  477 
microsomal enzyme (ranging from 0. 7 to 2.2 μM), and comparable to coumarin affinity for 478 
microsomal CYP2A5 (ranging from 0.5 to 2.0 μM) (Abu-Bakar et al., 2012; Abu-Bakar et 479 
al., 2005; Draper et al., 1997; Kinonen et al., 1995). Importantly, BR affinity for 480 
mitochondrial and microsomal CYP2A5 (0.5 to 2.7 μM) appears to be similar (unlike that of 481 
coumarin) and optimal for maintaining the intracellular BR concentrations at sub-toxic levels 482 
of <10 µM. 483 
 484 
Effect of pyrazole on the release of cytochrome c from mitochondria 485 
 Cytochrome c — a component of the mitochondrial ETC — is often released from 486 
mitochondria during the early stages of apoptosis when mitochondrial membranes were 487 
severely damaged (Sanchez-Alcazar et al., 2000). Once in the cytosol, cytochrome c initiates 488 
the process of apoptosis. Hence, analysis of this protein in mitoplasts and cytosol will give a 489 
glimpse on whether or not PYR treatment caused severe damage to mitochondrial membrane.  490 
Fig. 8 shows that PYR treatment did not cause the release of cytochrome c protein into the 491 
cytosol. The cytochrome c is primarily concentrated in the mitoplasts, which is in agreement 492 
with previous observations that the protein is tightly bound to the inner membrane by 493 
cardiolipin, a phospholipid found primarily in the mitochondrial inner membrane (Cortese et 494 
al., 1998; Gallet et al., 1997; Gorbenko, 1999; Rytomaa et al., 1995).  495 
 The observed lack of cytochrome c leakage suggests that despite a significant increase 496 
(> 200%) in mitochondrial HMOX1 activity (Table 1) — the enzyme that produces BR —  497 
mitochondrial BR levels were well below the concentration range (> 10 μM) that disrupts 498 
mitochondrial membrane permeability (Rodrigues et al., 2002). The observation is also 499 
aligned with the observed reduction of mitochondrial protein carbonylation after PYR 500 
treatment (Fig. 2A). 501 
 502 
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Discussion  503 
 In the present study we have demonstrated that HMOX1, BVR and CYP2A5 — the 504 
enzymes critical for maintaining hepatic intracellular BR levels optimal for its antioxidant 505 
role — are targeted to mitochondria in response to PYR-induced oxidative stress. The 506 
treatment regime evoked oxidative stress as indicated by nuclear translocation of cytoplasmic 507 
Nrf2, as well as carbonylation of cellular proteins, particularly to endoplasmic reticulum 508 
proteins, which aligns with previous findings (Cederbaum, 2013; Gilmore and Kirby, 2004; 509 
Lu et al., 2008). 510 
The CYP2A5, a BR oxidase, in particular is strongly upregulated in the mitochondria 511 
and is also adapted to be part of the mitochondrial ETC. Interestingly in this condition, 512 
microsomal UGT1A1, the sole enzyme that catalyses BR elimination via glucuronidation is 513 
not targeted to mitochondria. By contrast, the activity of BVR, the enzyme that catalyses BV 514 
reduction to BR is increased in the mitochondria. Collectively, these observations and the fact 515 
that the major metabolite of the CYP2A5-catalysed BR oxidation is BV, indicate that 516 
oxidative stress creates local conditions in mitochondria for increased capacity of the BR-517 
BV-BR loop, which does not favour BR elimination. It is plausible that the loop is associated 518 
with heightened mitochondrial antioxidant capacity as indicated by reduction of 519 
mitochondrial proteins carbonylation and lack of cytochrome c leakage into the cytoplasm. 520 
 It is essential to note the different purposes of the three different metabolic routes of 521 
BR. Firstly, BR conversion to BV by the CYP2A5 does not aim at its elimination, instead to 522 
reduce its toxicity and to keep it in the cells for later use as supported by previous 523 
observations (Abu-Bakar et al., 2011; Abu-Bakar et al., 2012). Secondly, the purpose of 524 
random BR oxidation by ROS to dipyrroles — which are excreted in the urine (Arthur et al., 525 
2012; Kobayashi et al., 2003) — is to protect cells and mitochondria against oxidative 526 
damage. Lastly, the well-known UGT1A1-catalysed glucuronidation pathway is important in 527 
the clearance of excessive amounts of circulatory BR (McDonagh, 2010) and is not involved 528 
in regulating minute intracellular levels of BR. The absence of this pathway in mitochondria 529 
further emphasise the importance of BR oxidation in managing intracellular BR. It is thus 530 
plausible that the random BR oxidation by ROS protects cellular structures against oxidative 531 
stress, whilst the enzymatic BR oxidation protects cells against excessive intracellular BR — 532 
which mechanism predominates would depend on the levels of intracellular ROS and BR. 533 
 In the case of mitochondria our observations suggest that under normal condition BR 534 
oxidation by ROS predominates that of the enzymic oxidation, presumably to protect 535 
mitochondria against ROS-mediated damage. Under oxidative stress conditions — when 536 
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local BR production is heightened due to increased HMOX1 activity — the ROS and 537 
enzymic oxidation of BR is equally important. This indicates that in a risk situation of 538 
structural damage, recruitment of microsomal HMOX1 and CYP2A5, and cytosolic BVR to 539 
mitochondria elevates local cytoprotective capacity to confer protection against elevated ROS 540 
and the potential toxic effects of excessive BR. This proposition is supported by our 541 
observations that mitochondrial proteins carbonylation was significantly reduced and that 542 
mitochondrial cytochrome c was not released to the cytosol in treated animals.  543 
 Cytochrome c is tightly anchored in the inner membrane by binding to cardiolipin 544 
(Cortese et al., 1998; Gallet et al., 1997; Gorbenko, 1999; Rytomaa et al., 1995). Thus, it has 545 
been proposed that the release of this protein into the cytosol involves its detachment from 546 
the inner mitochondrial membrane by disruption of the cardiolipin–cytochrome c complex, 547 
which is followed by permeabilisation of the outer membrane and the release of cytochrome c 548 
into the cytoplasm (Ott et al., 2002). In a study with rat liver mitochondria, Ott et al (2002) 549 
demonstrated that permeabilization of the outer membrane or disruption of the cardiolipin–550 
cytochrome c complex, alone, does not sufficiently trigger the release of cytochrome c. 551 
Additionally, the observations that cardiolipin confers fluidity and stability of the inner 552 
membrane (Lesnefsky et al., 2001; Ostrander et al., 2001; Paradies et al., 2000) and that 553 
oxidation of cardiolipin by mitochondrial ROS solubilises  cytochrome c (Kagan et al., 2005; 554 
Ott et al., 2002; Shidoji et al., 1999), suggest that damage to the inner membrane is required 555 
for the release of cytochrome c. Accordingly, our results indicate that the inner membrane has 556 
not been severely damaged to cause the release of cytochrome c to the cytoplasm. It is thus 557 
plausible that induced recruitment of key BR regulatory enzymes to mitochondria occurred 558 
prior to severe membrane damage. This proposition is supported by the observed elevated 559 
nucleo-Nrf2 levels, which indicates initiation of a downstream cytoprotective mechanism. 560 
Indeed, Nrf2 has recently been implicated as a new therapeutic target for the treatment of 561 
liver fibrosis (review in Yang et al., 2013). 562 
 Importantly, enzymic bilirubin-oxidizing activity has been described earlier in the liver 563 
and brain mitochondria, and has been suggested as the major metabolic pathway for 564 
mitochondrial BR but the enzyme(s) involved has not be identified (Cardenas-Vazquez et al., 565 
1986). Our present findings confirmed the earlier observations and identified CYP2A5 as the 566 
mitochondrial BR oxidase.  567 
 We surmise that our preliminary data clearly demonstrate that the recruitment of key 568 
BR regulatory enzymes into mitochondria is an adaptive response to PYR-induced oxidative 569 
stress, potentially to protect mitochondria against severe oxidative damage. The placement of 570 
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a local system to regulate mitochondrial BR homeostasis is perhaps to protect the organelles 571 
against ROS generated by mitochondrial respiration and from exposure to toxic chemicals. 572 
Our future studies aim at further understanding the role of mitochondrial BR regulating 573 
enzyme system in cytoprotection and in mitochondria associated diseases.    574 
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Table 1: Activities of coumarin 7-hydroxylase, haem oxygenase and biliverdin reductase in 762 
the livers of control and PYR-treated mice.  763 
 764 
Enzyme 
Activity 
 Cytosol Microsomes Mitoplasts 
CTR PYR CTR PYR CTR PYR 
COH
#
 ND ND 743 ± 99 7329 ± 500
*
 10 ± 1 622 ± 53
*
 
HMOX
##
 ND ND 260 ± 23 964 ± 63
*
 83 ± 10 295 ± 30
*
 
BVR
##
 30 ± 2 36 ± 10 ND ND 24 ± 5 45 ± 1
*
 
 765 
CTR = control; PYR = pyrazole. 
#
Coumarin 7-hydroxylase activity; pmol 766 
umbelliferone/min/mg protein; 
##
Haem oxygenase (HMOX) and biliverdin reductase (BVR) 767 
activities; pmol BR/min/mg protein. CTR, control; PYR, pyrazole. The values are of 3 768 
separate pools each consisting of 2 animals. Values were normalized against percentage of 769 
microsomal contaminations. 
*
Mean difference is significant from control group at p < 0.05 770 
(Student t-test).  771 
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Figure legends 772 
Figure 1: Estimation of the purity of microsomes and mitoplasts. Mice (N = 12) were 773 
administered 200 mg pyrazole/kg/day for three consecutive days or normal saline. Twenty-774 
four hours after the final dose, liver mitoplasts and microsomal fractions were prepared. (A) 775 
After SDS-PAGE electrophoresis, gels were blotted on PVDF membranes, which were then 776 
probed with antibodies specific for either endoplasmic reticulum (NPR) or mitoplasts 777 
(COXIV) marker proteins. Each blot represents one of three blots (each blot showed the same 778 
pattern of induction).  The amounts of protein (µg) loaded on the gels are indicated. Positive 779 
control (+) = NPR and COXIV peptides. (B) The activities of NPR and COXIV in mitoplasts 780 
and microsomes from livers of PYR-treated and control mice. CTR, control; PYR, pyrazole. 781 
The values are of 3 separate pools each consisting of 2 animals and were normalized against 782 
percentage of microsomal contaminations. *Mean difference is significant from control group 783 
at p < 0.05. 784 
 785 
Figure 2: Effects of pyrazole treatment on biomarkers of oxidative stress. Mice (N = 12) 786 
were administered 200 mg pyrazole/kg/day for three consecutive days or normal saline. 787 
Twenty-four hours after the final dose, liver cytosol, microsomes, mitoplasts, and nuclei were 788 
isolated. (A) Protein carbonyl contents in cytosol, microsomes and mitoplasts of control and 789 
treated livers. (B) Nrf2 antibody-immunoreactive protein levels in cytosol and nuclei. 790 
Electrophoresis was performed with 20 µg cytosolic and nuclei protein.  The proteins were 791 
blotted and probed with anti-Nrf2 antibody (1:500 dilutions). Shown are representative of 792 
three blots (each blot showed the same pattern of induction). Nuclear extracts from HeLa 793 
cells treated with 50 μM CdCl2 for 4, whole cell lysates from HeLa cells, and β-Actin peptide   794 
were used as positive control (+) for Nrf2, Lamin B1 and β-actin, respectively. β-Actin and 795 
Lamin B1 served as loading control for cytosolic and nuclei proteins, respectively. (C) 796 
Densitometry analysis of the blots probed with the various antibodies. Relative density = 797 
density of signals from protein of interest relative to density of loading control signals. CTR, 798 
control; PYR, pyrazole. The values are means of 3 separate pools each consisting of 2 799 
animals and were normalized against percentage of microsomal contaminations.
*
Mean 800 
difference is significant from control group at p < 0.05. #Mean difference is significant from 801 
cytosol and microsomes control groups at p < 0.05 802 
 803 
Figure Captions
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Figure 3: Effects of pyrazole treatment on induction of BR regulatory enzymes. Mice (N = 804 
12) received doses of PYR (200 mg/kg) on three consecutive days. Twenty-four hours after 805 
the final dose, liver cytosolic, microsomal and mitoplasts fractions were prepared. (A) 806 
CYP2A5, HMOX1, BVR and UGT1A1 antibody-immunoreactive protein levels in cytosol, 807 
microsomes and mitoplasts. The amount of protein loaded on the gel for each subcellular 808 
fraction was 25 μg. Each blot represents one of three blots (each blot showed the same pattern 809 
of induction). Positive controls (+) = CYP2A5 recombinant protein and peptides of HMOX1, 810 
UGT1A1 and BVR. (B) Densitometry analysis of the blots probed with the various 811 
antibodies. Relative density = density of signals from protein of interest relative to density of 812 
loading control signals. CTR, control; PYR, pyrazole. The values are of 3 separate pools each 813 
consisting of 2 animals and were normalized against percentage of microsomal 814 
contaminations. *Mean difference is significant from control group at p < 0.05. 815 
 816 
Figure 4: Effect of pyrazole treatment on microsomal and mitochondrial BR disappearance 817 
rates. (A) Liver microsomes and mitoplasts (10 µg protein) were incubated in reaction 818 
mixtures containing 1.5 mM NADPH. The reaction was initiated by addition of 20 µM BR 819 
and absorbance at 440 nm was recorded for 20 cycles at 1 min/cycle. The rate of BR 820 
disappearance is expressed as pmol BR disappearing/min/mg protein, using a εmM=41.15 821 
cm−1, which was obtained experimentally under the conditions of the assay. All experiments 822 
were done in the dark and 2 mM (final concentration) of EDTA was added in all incubation 823 
mixtures. (B) Inhibition of microsomal and mitochondrial BR disappearance rate by 200 mM 824 
vitamin C. CTR, control; PYR, pyrazole. The values are of 3 separate pools each consisting 825 
of 2 animals and were normalized against percentage of microsomal contaminations. *Mean 826 
difference is significant from control group at p < 0.05 (Student t-test).  827 
 828 
Figure 5: Summary of the oxidative products of bilirubin formed in the chemical and 829 
enzymic systems. (A) Chemical oxidation of BR by the Fe-EDTA/H2O2 system produced the 830 
putative dipyrroles. (B) Bilirubin incubations with microsomes or mitoplasts produced both 831 
biliverdin and the putative dipyrroles. *Significant different from control group, p<0.05 832 
(Student t-test). 833 
 834 
Figure 6: Effects of anti-CYP2A5 and anti-AdxR antibodies on bilirubin degradation activity 835 
in microsomes and mitoplasts. (A) Inhibition of bilirubin degradation activity in control and 836 
treated microsomes in the presence of anti-CYP2A5 antibody (▪) and in the presence of serum 837 
 25 
 
IgG (▫). (B) Inhibition of bilirubin degradation activity in control and treated mitoplasts in the 838 
presence of anti-CYP2A5 antibody (●) and in the presence of serum IgG (○). The antibody 839 
was added in increasing amount so as to achieve the antibody to microsomal/mitochondrial 840 
protein concentration ratios indicated. (C) Treated microsomes or mitoplasts were incubated 841 
with BR in the presence of absence of anti-AdxR antibody. The antibody was added in 842 
increasing amount so as to achieve the antibody to microsomal/mitochondrial protein 843 
concentration ratios indicated. CTR = control; PYR = pyrazole; AdxR, adrenodoxin 844 
reductase. The values are of 3 separate pools each consisting of 2 animals.  845 
 846 
Figure 7: Effect of bilirubin on 7-hydroxylation of coumarin in mitochondria.  (A) 847 
Mitoplasts were incubated with various concentrations of coumarin in the presence of 848 
increasing amounts of BR. The rates of coumarin 7-hydroxylation were determined by 849 
fluorescence spectroscopy. The formation of 7-hydroxycoumarin by mitochondrial CYP2A5 850 
followed simple Michaelis–Menten kinetics. (B) BR increased the Km and reduced the Vmax 851 
of coumarin 7-hydroxylation. (C) Km observed vs BR concentrations plot indicates that BR is a 852 
competitive inhibitor with Ki = 2.67 μM.  853 
 854 
Figure 8: Effects of pyrazole on cytochrome c protein expression. (A) Western blot analysis 855 
of cytosolic and mitoplasts proteins from livers of control and pyrazole-treated DBA/2J mice 856 
probed with anti-cytochrome c antibody. Cytochrome c peptide was used as a positive control 857 
(+). (B) Densitometric analysis of cytochrome c blots. The means ± SD are of three separate 858 
pools each consisting of two animals.  859 
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